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Kurzfassung 
 
Unter den 110 MYCN amplifizierten (MNA) Neuroblastomen, die in den letzten 10 Jahren am 
CCRI analysiert wurden, befanden sich 26 Tumore mit variierender Anzahl von Tumorzellen 
oder Arealen ohne MNA. In Übereinstimmung mit den Richtlinien der INRG Biologie 
Gruppe wurden diese Tumore als „heterogen MYCN- amplifiziert (hetMNA)“ eingestuft. Da 
der genomische Hintergrund von hetMNA- Tumoren bis jetzt noch nicht beschrieben wurde, 
versuchten wir Gemeinsamkeiten in segmentalen und/oder nummerischen Aberrationen (SCA 
und/oder NCA) zu finden. Von bis zu vier Tumorstücken vom selben hetMNA Tumor von 
fünf Patienten wurden Kryoschnitte angefertigt. Insgesamt wurden 13 Stücke mit Interphase 
FISH (I-FISH) analysiert und ihre DNA zur Aufklärung des genomischen Hintergrunds in 
hetMNA Tumoren mit MLPA und SNP Arrays untersucht. MYCN-Heterogenität wurde mit I-
FISH detektiert und in Kombination mit der DDX1-Sonde angewendet um die 
Amplikonzusammensetzung festzustellen. γH2AX- Färbung mit anschließende MYCN FISH 
wurde durchgeführt um das Auftreten von DNA-Doppelstrangbrüchen mit MNA zu 
korrelieren. Die Quantifizierung der Signale auf den Schnitten wurde mit einem 
automatischen Aufnahmesystem durchgeführt. Alle analysierten hetMNA-Tumore zeigten 
NCAs, wobei zwei Proben von je zwei Patienten nur NCAs zeigten, sechs Stücke von vier 
Tumoren zweier weiteren Patienten wiesen zusätzlich unterschiedliche SCAs auf. Drei von 
vier Stücken von einem Patienten zeigten ebenfalls nur NCAs, das vierte eine SCA. 
Zahlreiche Chromosomen waren überrepräsentiert. MNA wurde in je einem Tumorstück von 
vier Patienten mit MLPA und/oder SNP Arrays bestätigt, während der fünfte MNA nur mit 
MYCN-FISH zeigte. In einem Tumor wurde Heterogenität in der Amplikonzusammensetzung 
bewiesen und ein anderer zeigte zwei unterschiedliche 1p-Bruchstellen in vier Stücken. Das 
Muster der γH2AX-Färbung korrelierte bedingt mit MNA-Tumorzellen. Unsere Daten 
belegten die Existenz von mehreren Tumorzellklonen und zum Teil unterschiedlichen 
Amplikons im gleichen Tumor. Mit der angewendeten Auflösung konnte jedoch keine SCA-
Gemeinsamkeit gefunden werden, welche MNA bedingen könnte. Es konnten keine 
eindeutigen Rückschlüsse gezogen werden, dass genomische Instabilität MNA auslöst. Wir 
können die Notwendigkeit einer detaillierten Tumoraufarbeitung mit I-FISH und DNA-
basierenden Techniken, wie sie von der International Neuroblastoma Research Group (INRG) 
Biology Group vorgeschlagen wird, nur bestätigen, um Heterogenität festzustellen. 
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Abstract 
 
Among 110 MYCN amplified neuroblastomas analyzed at the CCRI in the last decade, 26 
tumors contained a varying number of tumor cells/areas without MNA, defined as 
heterogeneous MYCN amplification (hetMNA) according to INRG biology guidelines. Since 
the genomic background of hetMNA tumors has not yet been described, we looked for 
common segmental and/or numerical chromosome aberrations and genetic instability as 
initiators for amplicon formation. Up to four tumor pieces of the same hetMNA tumor from 
five patients were cryosectioned. In total, thirteen pieces were analyzed by I-FISH and their 
DNA was analyzed by MLPA and 250k SNP arrays to investigate the genomic background of 
hetMNA tumors. MYCN I-FISH was performed to detect MYCN heterogeneity and combined 
with DDX1 probes to assess the amplicon composition. γH2AX staining and subsequent 
MYCN FISH was performed to correlate DNA double strand breaks occurrence with MNA. 
Quantification of signals on the sections was done with an automatic device. All analyzed 
hetMNA tumors showed NCAs, two samples from two patients each showed only NCAs; six 
pieces from four tumors from two patients displayed a variety of inconsistent, additional 
SCAs. Three of four pieces from one tumor had only NCAs, the fourth one SCA. Numerous 
chromosomes were unitarily found overrepresented. MNA was confirmed in four tumor 
pieces of four patients by MLPA/SNP arrays, the fifth showed MNA only in its MYCN FISH 
results. One tumor revealed different amplicon compositions in the same piece and another 
showed two 1p-breakpoints in four pieces. γH2AX staining pattern only partially correlated 
with MNA cells. Our data indicates the existence of multiple tumor cell clones and different 
amplicons in single hetMNA NBs. At the applied resolution, no common SCA is found to be 
underlying MNA not excluding subtle genomic changes and mutations. A conclusion on 
genetic instability as a cause for MNA is premature. Our data strongly supports a detailed 
tumor work up and the application of both I-FISH and DNA-based techniques as 
recommended by the INRG. 
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1 Introduction  
1.1 Neuroblastoma – a pediatric tumor  
 
Neuroblastoma is a solid form of cancer developing in the extracranial nervous tissue. As a 
common pediatric tumor with 6-10% of all reported cancer cases in children, its onset timed 
during early childhood but may already occur prenatally. Neuroblasts originating from the 
neural crest are the common progenitors of the sympathetic nervous system and the major 
component of NB tumors. Migration during embryonic development leads to a spread of this 
cell type which also reflects the pattern of the latter development of the primary disease and 
the multiple locations NB tumors can be found in [1]. The abdominal cavity with adrenal 
(40%) and paraspinal ganglia (25%) is the most frequent primary location of the tumor 
commonly detected in older children. Other initial sites are thorax (15%) and cervix (3%) 
predominantly found in infants. Pelvis (5%) and miscellaneous sites (12%) add to the 
diversity of the primary tumor locations. 
NB is a heterogeneous disease which largely affects therapy protocol and correlates with 
the prognosis for recovery of the patient. The severity of the disease is assessed in the 
different risk categories low, intermediate, and high, which are set up by the International 
Neuroblastoma Staging System [2]. The severity and the clinical progression of NB can vary 
from spontaneous regression [3] and maturation [4] to aggressive malignant behavior. Recent 
findings suggest different emergence and molecular characteristics for tumors in the three 
different categories. Genomic imbalances occur either sequentially or simultaneously and are 
considered to be responsible for the heterogeneity of NB [5] and its clinical outcome. Tumors 
with the best prognosis and a chance of spontaneous regression in the low-risk category 
showed a hyperdiploid or near-triploid karyotype with whole-chromosome gains but without 
structural aberrations [5-7]. Near-triploid NBs are frequently associated with a localized 
phenotype of the tumor, lack of chromosomal structural alterations, and are diagnosed mostly 
in children of younger age [8]. Structural genomic aberrations of chromosomes usually 
correspond to a dismal prognosis and characterize the high-risk group. Tumors from children 
older than 18 month often belong to this category. Amplification of the proto-oncogene 
MYCN and the loss of the short p-arm of chromosome 1 (1p) are frequently occurring patterns 
in aggressive NB [9]. Loss of heterozygosity (LOH) of other segments like the short arm of 
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chromosome 3 (3p) and the long q-arm of chromosome 11 (11q), as well as gain 17q are also 
common contributors to an often fatal course of the disease in high-risk patients [6, 10-12]. A 
few alterations are frequently present in combination and determine a genetic subset of 
neuroblastoma. Segmental aberrations at 3p, 11q and 14q pose an example for such a 
collocation, which seems to be mutually exclusive of 1p-gain and MYCN amplification in a 
different subset [13]. Analyses showed that the pattern of structural changes usually develops 
sequentially but source and trigger need further investigation [5, 14 (in press)]. To complicate 
the search, NB is considered to be a sporadic form of cancer given that only a few hereditary 
cases are reported [15].  
 
 
1.2 MYCN amplification in aggressive neuroblastoma  
 
MYCN is a member of the MYC-family of transcription factors and maps to chromosome 2 
at 2p23-24 as demonstrated in human neuroblastoma cell lines [16]. The protein is a basic 
helix-loop-helix (bHLH) protein with the ability to bind DNA through dimerization. The 
proto-oncogene was first characterized through its amplification in human NB cells [17, 18] 
with a presence in approximately 23% of the investigated tumors. Normal expression of the 
gene is relevant in undifferentiated cell types during mammalian embryonic development [19, 
20]. MYCN, when amplified in postnatal cells, gained further significance as a clinical 
indicator for an aggressive form of NB with a poor prognosis for survival [21]. Additionally, 
the amplification of the gene was found in other tumors of neuronal nature including small 
cell lung cancer (SCLC), retinoblastoma, malignant glioblastoma, and peripheral 
neuroectodermal tumors (PNET)s [22-25]. MYCN is overexpressed in all these tumors. 
Mutations in the coding region of MYCN were not detected by DNA sequence analysis and 
can thus be excluded as a potential cause for the elevated gene expression contributing to 
tumorigenesis [26, 27]. In fact, the copy number amplification of up to 250-fold common in 
neuronal tumors is the reason for the cancerogenous property of MYCN. 
Amplification of DNA fragments and oncogenes, in particular, can be manifested as 
intrachromosomal homologous staining regions (hsr) or episomal double minutes (dmin). 
Both forms are considered to arise after DNA double-strand breakage and permitted by 
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erroneous DNA repair and non-functional cell cycle checkpoints. Intrachromosomal 
recombination [28], telomere fusion subsequent to double chromatid breakage at fragile sites 
[29, 30], or unequal sister chromatid exchanges accompanied by secondary rearrangements 
can result in short to large tandem duplications at locations close to the single-copy of the 
wild-type gene. Alternatively, amplification can take place at distant regions from the locus of 
the single-copy gene after reintegration of episomal DNA [31]. The most popular model for 
intrachromosomal amplification, however, is the breakage-fusion-bridge cycle which can be 
found in a number of solid tumors like prostate cancer, osteosarcoma, and squamous cell 
carcinomas [32-34]. Ultimately, multiple cycles lead to an amplification of genes adjacent to 
the breakage site which can result in both hsr- and dmin-formation. The amplified sequence is 
retained at its original chromosomal location. A different explanatory approach is the 
“episomal model” [35-37]. The target sequence is excised from the chromosome, circularized, 
and amplified subsequently producing dmin. Excision often leads to the deletion of the single-
copy at its normal position in the chromosome. Evidence for this model has been reported, for 
instance, in cases of acute myeloid leukemia [38].  
Support for both theories was also found in case of MYCN amplification in neuroblastoma. 
In addition to the retention of the single- copy at the original position, examined cell lines 
carried MYCN in amplified versions in hsr regions and double minutes [16, 39, 40 (in press)]. 
Indications for both cytological forms of the amplicon in a single tumor cell were also found 
arguing for a transition between both manifestations [39]. Dmin are thus potentially persistent 
copies of the oncogene en route to integration at a host region on a different chromosome 
[41]. More recent findings, especially contributed by the cell line STA-NB10, promoted the 
episome model [40 (in press)]. Analyzing the borders of the MYCN amplicon by sequencing 
revealed a close match with the remaining ends on chromosome 2 after deletion. Furthermore, 
the two subclones of the cell line, STA-NB10/dmin and STANB/hsr, confirmed the 
hypothesis that integration of dmin at a different chromosomal location can form hsr with the 
same amplicon sequence.  
The amplified region containing the MYCN gene can span DNA from 350kb to more than 
1Mb with a consistent core region between 130 and 258kb including the gene itself [42, 43]. 
Additional DNA segments in proximal and distal orientation to the oncogene can be amplified 
to account for the rest of the size. Genetic analysis of the amplicon proved the coamplification 
of DDX1, NAG, NSE1, and LPIN on the telomeric side, and EST-AA581763, SMC6 and SDC1 
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on the centromeric side with distance-dependant probabilities of coamplification (Figure 1) 
[44]. The effect of coamplification of neighboring genes in the MYCN amplicon on prognosis 
and disease outcome needs to be further elucidated. In case of DDX1, contradicting data has 
been published linking coamplification to faster relapse, on the one side, and beneficial 
prognosis and patient survival on the other [44, 45].  
 
 
Figure 1: Coamplification in the MYCN amplicon is distance-related [44]. (A) Coamplification frequencies 
of the seven investigated genes on chromosome 2p24-25 in 98 primary NB tumors. (B) Physical distance of the 
seven investigated genes in relation to MYCN, based on current BLAT assignment information [42] 
 
The MYCN gene in itself is generally not rearranged compared to its wild-type form and is 
usually amplified in a direct head-to tail tandem organization. A larger amplicon, however, 
undergoes internal rearrangements and deletions. During the course of the disease, the 
structure of the MYCN amplicon is considered to be invariable after the initial amplification 
process and found to be unchangeable in NB even by treatment [46]. Examination of the 
promoter region suggested that all copies of the gene can be transcriptionally active often 
resulting in the overexpression of the oncogene [47]. 
 
13 
 
1.3 Intratumoral heterogeneity in neuroblastoma  
 
By definition, heterogeneity in case of a disease refers to multiple etiologies of a medical 
condition. For instance, the cause of neuroblastoma is heterogenic in terms of different 
genomic alterations leading to the formation of a tumor in the extracranial nervous system. 
This kind of heterogeneity results in different stages and risk stratification of the tumor. 
MYCN amplification, loss of heterozygosity, gain of chromosome segments, whole 
chromosome aberrations, and ploidy in different combinations are characteristic for the 
aggressiveness of the tumor and relevant for its treatment. Additionally, patients were found 
with MYCN-amplified tumor cells in the bone marrow but showed no sign of amplification in 
the solid primary tumor, which is an example for heterogeneity in tumor cell populations in 
different locations of the body [48]. 
Intratumoral areas can also be genetically heterogeneous which was confirmed in multiple 
types of cancer. In some cases of renal cell carcinoma, heterogeneity in terms of DNA ploidy 
with different areas of diploid and aneuploid cells in the same tumor were detected [49]. 
Interphase FISH of meningiomas and flow cytometric analysis of small hepatocellular 
carcinoma evidenced a pattern of deviations in chromosome number among different cell 
clones [50, 51]. A study of human breast cancer, on the other hand, revealed heterogeneity 
concerning gene amplification within a tumor [52]. These are only a few examples of 
intratumoral heterogeneities, which relevant for the progression of the tumor and its treatment 
in some cases.  
Although reported to a lesser extent, neuroblastomas also show heterogeneous areas in 
confined tumors. Kerbl et al. reported a case of a patient with a trisomic karyotype for 
chromosomes 1 and 2 in the majority of primary tumor cells [53]. In the same study, MNA or 
imbalances of 1p36 were also detected in different focal areas within the tumor. However, the 
first NB case with MYCN heterogeneity at the CCRI was already discovered in 1991. 
Heterogeneous tumors that were registered with the CCRI in the last decade were on average 
detected at a patient’s age of 13 month. In contrast, patients with homogenous MNA tumors, 
that were included in the ANB94 study, were diagnosed with NB at an average age of 21 
month (I.M. Ambros; personal communication). This difference argues for an earlier onset or 
faster growth to a detectable size of heterogeneous tumors. Metastatic growth, however, 
seems to be decreased since 55% of the tumors were assigned to localized and the 4S stage 
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(I.M. Ambros; personal communication). Whether this percentage is related to age and minor 
progression of the tumor or a veritable characteristic of heterogeneous tumors remains to be 
investigated in more detail. Interestingly, only 19% of the homogeneous MNA NB was 
classified as localized or 4S stages (I.M. Ambros; personal communication). Amplification of 
MYCN in a homogenous tumor cell population likely leads to a more rapid tumor progression 
and possibly contributes to metastatic growth. Cells of this more aggressive nature also seem 
to have the ability to overgrow neighboring tumor cells of more favorable genetics by faster, 
uncontrolled proliferation [54, 55]. A recent study with 20 NB patients was published with 
conflicting results on the involvement of single MYCN-amplified cells in heterogeneous 
tumors in relapse, progression, and dissemination [48]. Cases were found to argue for and 
against a lead role of these few cells. In the end, the authors reasoned that a small number of 
MNA cells in a tumor do not correlate with an adverse outcome.  
In any case, the emergence of MYCN amplification resulting in heterogeneity of a localized 
NB tumor is only poorly understood and needs more focused investigation. For instance, it is 
not even known whether the heterogeneity in separate focal areas or defuse cells originates 
from one or multiple tumor cell clones and whether these cells even carry the same amplicon.  
 
 
1.4 Genetic instability in cancer 
 
Genome instability is considered to be an important hallmark of cancer as reviewed by 
Negrini et al [56]. A number of cancers have revealed substantial chromosomal instability 
(CIN) often resulting in segmental or whole chromosome overrepresentation, aneuploidy or 
loss of heterozygosity (LOH). To a lesser extent, genomic instability was also found to 
involve the numeral reduction or expansion of oligonucleotide repeats present in 
microsatellite sequences (microsatellite instability or MIN) [57, 58]. Increased frequencies of 
base-pair mutations afforded by defective base excision repair have also been reported [59]. 
Point mutation instability (PIN) as manifested by an elevated rate of single nucleotide 
mutations is another form of instability and considered to be an important contributor to 
intratumoral heterogeneity [60]. An attempt to combine all these forms into one postulate of 
coherence and causality was done with the mutator phenotype hypothesis [61]. Under the 
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premise that normal DNA mutation rates are insufficient to account for the numerous 
mutations in a tumor, a mutator phenotype of cancer cells ensures the required frequency of 
genome-wide, irreparable DNA damage. However, a universal key event for the 
transformation of a normal cell to a tumor cell with mutator phenotype has not been identified 
thus far. More probable is the assumption that initiation of transformation has multiple, 
interchangeable origins with reciprocal influence on one another. For instance, an increase in 
genome-wide PIN can contribute to the development of CIN and MIN alike, especially when 
DNA repair genes are mutated at random [62-64]. Many hereditary cancers present genomic 
instabilities preceded by mutations in genes involved in DNA maintenance and integrity or 
DNA damage checkpoint - the soi-disant caretaker genes. Genes with inhibitory function on 
tumor growth or activator function in the apoptosis pathway are considered gatekeepers. 
Inherited germline mutations of either class of genes leaves a person with a higher 
predisposition for cancer [65]. A prominent example is the mutation of the two breast-cancer-
susceptibility genes BRCA1 and BRCA2 leading to unresolved repair of DNA double-strand 
breaks and consequently to CIN [66]. Additional mutations of caretaker genes ATM and TP53 
certainly aid in the establishment of the mutator phenotype in breast cancer.  
Mutation of caretaker or gatekeeper genes is a plausible explanation for genomic instability 
in inherited cancers. On the contrary, identifying similar somatic events which frequently 
underlie tumorigenesis of sporadic cancers has been met with difficulties and was largely 
unsuccessful [67-69]. A second model to explain genomic instability and the occurrence of 
CIN, characteristic for almost all sporadic cancers, is based on DNA DSBs induced by 
oncogenes. Activation of oncogenes and subsequently of the growth signaling pathway leads 
to DNA replication stress [70]. Sequences that are prone to break under this stress after 
inhibition of replication are termed “common fragile sites” [71-73]. The consequent, stress-
related induction of LOH and genomic instability has been reported for mammalian cells in 
culture, mouse models and human xenografts [74-78]. For instance, within a single cell cycle, 
activated ras induces DNA DSBs in cultured NIH3T3 fibroblasts [76, 77]. Transcription 
factors MYC and E2F1, cell-cycle regulator Cyclin E, and the Mos protein kinase are 
expressed by other oncogenes which affect DNA integrity in a similar fashion [75, 76, 78, 
79]. Interestingly, a number of these oncogenes were evidenced to play a more important role 
in the induction of apoptosis and/or senescence, the natural barriers to tumorigenesis, than in 
tumor progression. Upon formation of DNA DSBs, the DNA damage response (DDR) 
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pathway is normally activated culminating in P53 phosphorylation and the successional 
induction of cell cycle arrest, apoptosis, or senescence depending on severity of DNA damage 
and success of its repair [80]. Hereditary and sporadic cancers alike need to circumvent these 
responses in order to progress from a precancerous lesion to an advanced tumor [74]. For this 
reason, a strong selective pressure is placed on mutations in DNA checkpoint genes and 
especially on p53, which consequently the most widely mutated gene in human cancers [81]. 
 
 
1.5 DNA double strand break response and the histone H2AX 
 
As previously stated, DNA double strand breaks are important initiators of genomic 
instability and involved in carcinogenesis [56]. Intracellular detection of DSBs leads to 
subsequent activation of the DSB response pathway. Members of the phosphoinositide 3- 
kinase (PI3K) - like family, namely the ataxia telangeictasia mutated (ATM), the ataxia 
telangeictasia and Rad3-related (ATR), and the DNA –dependent protein kinase (DNA-PK), 
are activated upon DSB formation and respond amongst other things by on-site 
phosphorylation of the downstream target H2AX at serine residue (Ser139) [82, 83]. 
Subsequently, phosphorylation of H2AX was shown to spread to molecules at increasing 
distance of the initial break site [84, 85]. This signal amplification cycle is induced by binding 
of the mediator of DNA damage checkpoint protein 1(MDC1) to γH2AX and the recruitment 
of the Mre11-Rad50- Nbs1 (MRN) complex leading to further stimulation of ATM [86]. 
Chromatin modifications required for the recruitment of tumor suppressor p53-binding 
protein 1 (TP53BP1) is another implication of the feedback loop [87]. This association 
establishes a link between DNA DSB detection and tumor suppressor p53-mediated cellular 
responses. Different signaling pathways are activated when more proteins are recruited as a 
direct consequence of phosphorylated γH2AX in order to converge to a successful repair of 
the DSB in the end. To name a few, MCPH1, a protein participating in sister chromatid 
condensation and cell cycle arrest, or other chromatin remodeling complexes involved in 
DNA repair accumulate at DSBs [88, 89]. ATR, induced by MCPH1, and ATM, 
phosphorylated by the γH2AX-mediated feedback loop, relay activation to checkpoint kinases 
CHK1 and CHK2 [90-92]. This process is considered to prevent entry into mitosis. Defective 
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components of the DSB response pathway are tied in one way or the other to malignancies 
and other diseases which further illustrates the importance of an accurate DNA repair.  
Ascertaining DSBs can be done by monitoring characteristics of certain members of the 
described response pathway. The intracellular localization of TP53BP1, phosphorylation 
status of Chk2, ATM and p53 or merely the p53 protein levels are commonly consulted as 
indicators for increased DNA DSB formation. Measuring γH2AX, however, is advantageous 
to the aforementioned techniques. Due to the amplification of the phosphorylation, larger foci 
are detectable by specific antibodies to the phosphorylated serine residue. Since these foci 
form at the nascent sites of DSBs, counting of γH2AX signals correlates well with the actual 
number of DSBs at least during the onset of repair [85, 93].  
As a member of the H2A-family of histones, H2AX is contained on average in every fifth 
nucleosome in fibroblasts. The contingent in the histone H2A pool can however vary between 
cell types from 2% in lymphocytes to up 20% in human glioma cell lines [94]. The human 
H2AX gene (H2AFX), mapping to 11q23.2 to approximately 11q23.3 on chromosome 11, 
shows implications to genomic stability in certain cancers when the gene is targeted by 
mutations or deletion [95, 96]. In case of head and neck squamous cell carcinoma, loss of 
distal 11q including the H2AFX gene is frequently reported to associate with DNA repair 
deficiency [97]. A population-based genetic association study in non-Hodgkin lymphoma and 
a genetic screen of sporadic breast cancer revealed a direct effect of genetic variation and 
copy number alterations in the H2AFX gene on susceptibility to tumor development [98, 99]. 
All this data supports the notion that H2AX acts as a mediator of tumor suppression [100].  
However, the direct affiliation of H2AX phosphorylation to genomic instability is not 
always feasible, since various factors account for DSB formation. In addition to a deficiency 
DNA repair of regularly occurring DSBs, direct interaction of DSB-inducing agents, reactive 
oxygen species (ROS), indirect interference of metabolites, eroded telomeres or viral 
infections originate DNA double strand damage [101]. Ionizing radiation (IR) and 
radiomimetic chemicals conduct a direct attack on DNA and exposure to these chemicals was 
thus linked to an increased risk of cancer development [84]. IR can also indirectly elicit DNA 
damage by interacting with cellular water to produce ROS, which can also be generated from 
endogenous metabolic sources, and were linked to carcinogenesis [102, 103]. ROS were 
shown to introduce DNA single strand breaks mostly during replication, which progress in an 
estimated 1% of the cases to double-stranded lesion [104]. The fact that metabolic processes 
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affect DNA integrity is exploited by numerous anticancer drugs, including cisplatin and 
hydroxyurea (HU), which interfere with the replication or transcription machinery resulting in 
DNA DSB formation. Hydroxyurea is an example for an alteration of the dNTP pool. HU 
inhibits the enzyme ribonucleotide reductase responsible for converting ribonucleotide 
triphosphate (NTPs) to deoxyribonucleotidetriphosphate (dNTPs) [105]. dNTPs are required 
in DNA replication. Other drugs, the camptothecins, inhibit cleavage of topoisomerase I 
(TOP1) by stabilizing its interaction with DNA and thus facilitate a potential collision with 
moving replication forks [106]. Such replication fork stalling often results in collapse and 
formation of DSB. The progression of topoisomerase II (TOPII) can also be compromised by 
binding of therapeutic agents like doxorubicin which stabilizes the TOPII-DNA complex after 
cleavage for tension release [107]. The DNA can thus not be resealed and DSBs are left 
behind. Attrition of telomeres in aging mammalian cells usually heads towards uncapped 
chromosomal ends when not maintained by telomerases. Since differentiated cells lack 
telomerases, unrepaired ends are detectable as DSBs by γH2AX [108]. The cellular response 
to irreparable DSB can also lead to age-related senescence [109]. 
Due to its sensitivity, detection of γH2AX is employed as a good tool for the assessment of 
cancer progression and therapeutic progress in clinic samples [101]. Additionally, organismal 
stress carried out by other environmental agents is increasingly determined by DNA damage 
induction and γH2AX foci formation.  
 
 
1.6 Neuroblastoma, genomic instability and DSB detection  
 
Neuroblastoma is a sporadic cancer with only a few documented hereditary cases [15]. 
Genetic heterogeneity of this solid tumor is manifested by the variety of segmental and 
numeric genetic aberrations detectable in primary tumors and after relapse. Genomic 
instability leads to the most frequently observed alterations including allelic loss of 
chromosome 11q and a gain of 17q. Other aberrations involve 1p, 1q, 2p, 3p, 4p, 9p, and 14q 
to name a few [13]. Common mutations in caretaker or gatekeeper genes are not listed among 
the various genetic abnormalities of NB and major oncogenic pathways seem spared from 
deregulation in primary tumors. Reported gatekeeper abnormalities were only accounted for 
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in NB cell lines. In case of p53, cell lines established after cyotoxic treatment and relapse 
have frequently shown an increase in mutation in p53 directly or other alterations affecting 
members of the p53/MDM2/ARF pathway [110, 111]. Ras is another oncogene which is often 
targeted by activating mutations and was shown together with mutated p53 and APC to be 
responsible for chromosomal aberrations in colorectal adenocarcinomas [112]. Although Ras 
can block MYCN degradation and thus promotes cell cycle progression in cultured LAN-1 
cells [113], an activating mutation of the oncogene has thus far not been detected in primary 
neuroblastoma, not even at advanced stages with MYCN amplification. The increase in copy 
number of MYCN is the only prevalent alteration of an oncogene in NB observed in around 
20% of primary tumors [114].  
The fact that only roughly a fourth of all neuroblastoma cases show a MYCN amplification 
permits the assumption that these tumors potentially carry one or a constellation of genetic 
factors predisposing for MNA, which non-amplified tumors do not. While two prominent 
hypotheses with the breakage-fusion-bridge cycle and the episome model have been 
established illustrating the actual mechanism of gene amplification [32-37], a universal trigger 
for this event and MYCN amplification in particular has not been found yet. For this reason, 
we focused on the examination of the genomic background in neuroblastoma looking for a 
common genomic aberration that might predispose for MNA. Since “classic”, homogeneous 
MNA tumors are already advanced in development, we chose to investigate the genetic 
profile of NB with heterogeneous MNA. The advantage of heterogeneous tumors lies in 
genomic data contributed by surrounding tumor cells without MNA. These cells might either 
still develop amplification themselves or play an independent role in triggering MNA 
formation in other tumor cells. Both genomic instability and the initial step of amplicon 
manifestation are closely tied to DSB formation. Therefore, our second, major focus was the 
investigation of DSB occurrence by γH2AX detection and subsequent correlation to the 
MYCN copy number in order to shed light on overall DNA integrity in MYCN-amplified cells. 
We also tested the suitability and accuracy of the standard NB diagnosis protocol set up by 
the INRG Biology Committee applied to detection of MNA heterogeneity and amplicon 
composition in neuroblastoma [115].  
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2 Patients, Materials and Methods 
2.1 Patients  
 
A total of thirteen tumor pieces of five neuroblastoma patients was analyzed in this study. 
Clinical and therapy data is summarized in Table 1. Staging was done in accordance with the 
International Neuroblastoma Staging System. All thirteen tumor pieces were collected from 
the tumor library of the Children’s Cancer Research Institute (CCRI, Vienna, Austria) and 
selected for their reported genetic heterogeneity in MYCN amplification. Reference samples 
of homogeneous tumors were grouped according to their MLPA profile and also taken from 
the CCRI tumor library.  
 
Patient # Stage 
Age at 
diagnosis 
Localization Therapy Outcome 
Number of 
tumor 
pieces 
1 3 3.5 years 
left-hand side part 
of abdominal 
cavity, infiltrating 
across the 
midline, kidney, 
spleen 
HR-NBL; 
autoSCT; 
radiotherapy; 
Roaccutane 
death 1 
2 2A 
11 
months 
thoracic-
abdominal 
INES CHT CR 4 
3 3 
10 
months 
adrenal right NB94 CR 2 
4 2B/4/4S 
11 
months 
thoracic left 
INES 
NB99.4 
CR 4 
5 3 9 months adrenal right NB94 CR 2 
Table 1: Clinical and therapy data of the five patients selected for genetic analysis.  
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2.2 Microscopic techniques  
2.2.1 Preparation of frozen patient material 
 
Patient tumor samples were embedded in Tissue Freezing Medium (Jung, Nussloch, 
Germany; Cat. No. 020108926) on metal specimen disks and cut at 5μm with Leica low-
profile disposable blades type 819 in a Leica CM1850 UV. Sections were picked on Premium 
HistoFrost Plus microscopic slides (Stölzle-Oberglas GmbH, Vienna, Austria; Prod. No.: 04-
2009) and stored at -20°C until further use.  
 
2.2.2 Histochemistry of frozen sections 
 
For histochemical analysis of the tumor samples, sections were stained with hematoxylin 
and eosin. Slides were placed in deionized water for 2 minutes to wash of the mounting 
medium before incubation in hematoxylin (Mayer’s hemalum solution for microscopy, 
filtered, Merck, Cat. No. 1.09249.0500) for 8 minutes. The blue color of the nucleus was then 
developed under running tab water, a process called blueing, for 30 minutes before treating 
the sections with eosin for up to 30 minutes depending on the age of the eosin (Eosin Y 
(Yellowish), Merck, Cat. No. 15935). Afterwards, the sections were dehydrated in an ethanol 
series (70% EtOH for 10sec, 96% EtOH for 2min, and 100% EtOH for 2min) before placing 
the slides into xylene for 10min. Then, slides were air-dried, embedded in Entellan rapid 
mounting medium for microscopy (Merck, Darmstadt, Germany; Cat. No. 1.07960) and 
covered with cover slips. Inspection of the tumor samples for sample quality, and tumor cell 
and stroma content was done with a Leica Axioplan 2 microscope in the transmitted light 
mode.  
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2.2.3 DNA probe labeling by nick translation for FISH 
 
The bacterial clones RP11-355-H-10 (AC010145, MYCN), 08–103-1 (chromosome2p), 
RP11-422-A-6 (DDX1) and RP11-685-A-8 (NAG) were obtained from Dr.
 
M. Rocchi 
(Resources for Molecular Cytogenetics, University
 
of Bari, Italy). 2µg of the respective DNA 
were combined with either DIG-Nick Translation Mix (Roche, Vienna, Austria; Cat. No. 
11745816910) containing 0.08 mM digoxigenin-11-dUTP or Biotin-Nick Translation Mix 
(Roche, Vienna, Austria; Cat. No. 11745824910) containing 0.08 mM biotin-16-dUTP 
respectively and the total volume adjusted to 40µl with ddH2O. The MYCN probe was labeled 
with DIG and the others with biotin. The solutions were incubated for 90minutes in a water 
bath at 16°C. To verify complete digestion and size (MYCN: 200 Kb) of the probes after the 
very first digestion, 5µl of the respective probe sample was run with 1µl loading buffer in a 
1.2% agarose gel at 100V and 500mA. Meanwhile the probes were kept on ice so that further 
nick labeling remained possible. The reaction was stopped by addition of 30µg of COT 
human DNA (Roche Diagnostics GmbH, Mannheim, Germany; Cat. No. 11581074001), a 
volume of NaAc (3M, pH 5.5, Merck, Darmstadt, Germany; Cat. No. TA636468) calculated 
as 1/10 of the probe volume plus the Cot- DNA volume and 2.5 times the volume of the 
solution of ice cold 100%EtOH (Merck, Darmstadt, Germany). Precipitation of labeled DNA 
probes was achieved by incubation at -80°C for a minimum of 30 minutes. The following 
centrifugation was done for 30 minutes at 13000 rpm at 4°C with a Hereaus Biofuge pico. 
After discarding the supernatant, the pellet was resuspended in 70% EtOH (local Pharmacy, 
Vienna) followed by centrifugation for 15 minutes at 13000rpm at 4°C. The supernatant was 
again removed and the DNA pellet dried for 5 minutes at RT. Resuspension of the probe was 
done in 40µl of a master mix and the DNA dissolved at 37°C in an Eppendorf thermomixer 
compact. The probe mixes were stored at 4°C until further usage.  
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2.2.4 Two-color interphase fluorescent in situ hybridization  
 
Cryosectioned slides were placed into 1xPBS for 5 minutes prior to fixation with 4% 
paraformaldehyde (Roti-Histofix 4%, Roth, Karlsruhe, Germany; Cat.No. P087.3) for 12 to 
14 minutes at 4° C. Sections were then either permeabilized with 0.1%Triton X100 in 1xPBS 
for 5min at RT or permeabilized with 0.5% Triton X100 in 1xPBS for 5min at RT, washed 
twice with 2xSSC for 5minutes before and after incubation with 100µl of 0.1mg/ml RNase 
(Sigma-Aldrich, Germany; Cat. No. R-5000). After permeabilization with or without RNA 
digestion, the sections were treated with a 0.005 µg/µl pepsin-containing solution for protein 
digestion. Incubation time depended on the exposition of cells to the enzyme. The progress of 
digestion was controlled under a Zeiss Axioplan 2 microscope in the transmitted light mode. 
If cells needed more digestion, the slides were placed into the Pepsin solution again. General 
incubation times varied between ½ and 1 minute. After digestion, the slides were washed 
twice with 1xPBS for 5 minutes at RT before dehydration in an ethanol series (70%, 96%, 
100% EtOH for 2 minutes each) and air-drying of the sections. Depending on the area of the 
section, 1µl to 2µl of each respective nick-labeled probe were applied to the section. Slides 
were then covered with a coverslip and sealed with rubber cement (Fixogum, Marabu, Tamm, 
Germany; Cat. No. 290110000). Denaturation of probe and target DNA was performed on a 
hot plate (Präzitherm, Störcktronic) at 78°C for 8 minutes. The slides were incubated for 
hybridization over-night or over the weekend in a moist chamber in a Haereus incubator at 
37°C. Following incubation, the slides were washed for 5 min in 2 x SSC at RT. For 
stabilization of the DNA::probe duplex, the sections were incubated for 15 min in 50% 
formamide in 2 x SSC and rinsed twice with 2 x SSC both at 42°C. The labeled probes were 
then detected with the respective antibody either against digoxigenin or biotin in a dilution 
with 2% bovine serum albumin (BSA) (Sigma-Aldrich)/1xPBS. A volume of 100µl of a 
mixture of a mouse Cy3-conjugated IgG Anti biotin (Jackson Immuno Research Laboratories, 
Cat. No. 200-162-096) diluted 1:500 and sheep anti-digoxigenin FITC-conjugated antibody 
(Enzo Life Sciences, Inc., Farmingdale, NY, USA; Cat. No. 12077441) diluted 1:100 was 
used for probe detection. Incubation was performed in a moist chamber at 37° C for 30 to 45 
min followed by washing twice for 7 minutes in 4 x SSC/ 0.1% Tween 20 at 42° C. 
Secondary antibodies diluted in 2% BSA/1xPBS, were incubated in a moist chamber at 37°C 
for 30 minutes followed again by the washing procedure described above. Fixation of the 
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staining was achieved by incubation of the slides in 4% paraformaldehyde in 1x PBS for 20 
minutes at 4° C, followed by washing twice for 5 minutes in 1x PBS, dehydration in EtOH as 
above and air drying in the dark. Slides were mounted with Vectashield (Vector, Burlingame, 
Ca, USA; Cat. No. V0305) supplemented with DAPI, covered with a cover slip, and sealed 
with rubber cement. Slides were photographed with an Axioplan2 fluorescence microscope 
(Zeiss, Austria) and images analyzed with the ISIS V 5.2.20 software by MetaSystems 
(Altlussheim, Germany). 
 
2.2.5 γH2AX immunohistochemistry on cryosections  
 
For the detection of DNA double strand breaks on a cellular basis, cryosections of tumor 
samples were stained for the histone variant γH2AX and subsequently hybridized with MYCN 
FISH probe. Cryosections were either air dried at room temperature following sectioning or 
thawed after storage at -20°C. After a washing step with 1xPBS at RT for 5 minutes for the 
removal of the Tissue Freezing Medium, the sections were fixed in methanol/acetone (1:1) at 
-20°C and washed again with 1xPBS for 5minutes. The slides were then fixed for 15 minutes 
at RT with 4% paraformaldehyde (Roti-Histofix 4%, Roth, Karlsruhe, Germany; Cat.No. 
P087.3) before washing three times with 1xPBS for 5 minutes each at RT. Afterwards, the 
sections were permeabilized with 0,1% TritonX100, 0.1% SDS in 1xPBS for 6 minutes at RT. 
The tissue was blocked with a blocking solution of 5% goat serum (normal) (Dako, Denmark; 
Code X0907), 1% BSA in 1xPBS. The anti-phospho-histone H2A.X (Ser139), clone JBW301 
antibody from Millipore, Vienna, Austria (Cat. No. 16-202A) was diluted 1:500 with a 
solution of 1% goat serum (normal), 1% BSA in 1xPBS. The sections were incubated with the 
antibody solution for 60 minutes in an incubator at 37°C. The slides were washed three times 
while slowly shaking with 1xPBS for 5 minutes at RT. The Cy3-labeled goat-anti-mouse 
secondary antibody was applied at a 1:500 dilution with 2% filtered BSA for 45 minutes in a 
37°C incubator. After two additional washing steps, the slides were counterstained with a 
2µl/ml DAPI (Sigma-Aldrich, Germany; Cat. No. D9542) in 1xPBS solution for 1 minute at 
RT. The DAPI solution was removed by washing while gently shaking with 1xPBS for 10 
minutes at RT. The sections were then covered with Vectashield (Vector, Burlingame, Ca, 
USA; Cat. No. V0305) and a cover slip and sealed with rubber cement.  
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Single images were taken with the Metafer 4 software by MetaSystems (Altlussheim, 
Germany) on a Zeiss Axioplan2 fluorescence microscope (Zeiss, Austria) run in an automatic 
mode at a 40-fold magnification. The integrations time for the detection of Cy3-labeled 
γH2AX and DAPI was fixed. The single images were stitched to an overview of the entire 
section with the MetaSystems Virtual Slide software.  
 
2.2.6 MYCN I-FISH on γH2AX- prestained tumor sections  
 
To correlate the occurrence of DSBs with MYCN amplification in neuroblastoma, MYCN I-
FISH was performed on γH2AX- prestained tumor sections. Coverslips were removed and the 
slides washed twice in 1xPBS for 5 minutes at RT. Sections were then permeabilized with 
0.5% TritonX100 in 1xPBS for 5 minutes at RT before washing the slides twice with 2xSSC 
for 5 minutes each. RNA was digested with 0.1mg/ml RNase (Sigma-Aldrich, Germany; Cat. 
No. R-5000) at 37°C for 60 minutes before washing the sections twice again with 2xSSC. 
Slides were then incubated for 30 seconds in a pepsin-containing solution and washed twice 
with 1xPBS for 5 minutes each at RT. Afterwards, the sections were dehydrated in an ethanol 
series (70%, 96%, 100% EtOH for 2 minutes each) and air dried. 3µl of the DIG-labeled 
MYCN FISH probe were applied to a section. The rest of the procedure largely followed the 
instructions described in 2.2.5. For detection of the DIG-labeled MYCN probe, a sheep anti-
digoxigenin, FITC-conjugated antibody (Enzo Life Sciences, Inc., Farmingdale, NY, USA; 
Cat. No. 12077441) was diluted 1:100 in 2%BSA and applied for 45 minutes at 37°C.  
Single images were taken automatically with a position list of the field-of-vision (FOV; 
(MetaSystems)) coordinates of the corresponding γH2AX-stained sections and section 
overviews were obtained as described in 2.2.5. The integrations time for the detection of 
FITC-marked MYCN was fixed. Correlation of single γH2AX- and MYCN-FISH-stained 
images was done manually with imageJ 1.40g (National Institutes of Health, USA). 
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2.3 Genomic evaluations of tumor samples 
2.3.1 DNA extraction from tumor samples  
 
For DNA extraction, the tumor was cut into smaller pieces and put into a pp-tube. The 
sample was then washed and spun down with an erythrocyte lysis buffer at 500g (~1700rpm) 
for 5 minutes with a Heraeus multifuge 1S-R centrifuge (Thermo Scientific). The supernatant 
was discarded and 3ml lysis buffer, 25µl Proteinase K (20mg/ml) (Sigma-Aldrich, Germany; 
Cat. No. P-6556), and 125µl SDS (20%) added in this order to the pellet. The sample was 
incubated at 56°C over night. After the overnight incubation, 1ml 6M NaCl was added to the 
lysis buffer- mix and centrifuged at 3450g for 30 minutes. The supernatant was then 
transferred to a new tube and the DNA precipitated with 2x vol. of 100% EtOH. Afterwards, 
50µl 1x TE buffer was filled into an Eppendorf tube in advance, before transferring the DNA 
precipitate. The DNA was stored at 4°C until further use. 
 
2.3.2 Multiplex ligation-dependent probe amplification (MLPA) 
 
MLPA is a variation of the standard polymerase chain reaction (PCR) reaction and permits 
multiple DNA targets to be amplified by a single primer pair ligated to different probes. The 
DNA sample was diluted to around 100ng/5µl end concentration with 1x TE-buffer in a 0,5ml 
PCR tube. The MLPA procedure requires 15µl of the DNA dilution. For each DNA sample, 
5µl were pipetted into three different 0,5ml PCR tubes. The tubes were placed into a T3000 
thermocycler from Biometra and the DNA was denatured at 96°C for 5 minutes and cooled 
again to 25°C. Afterwards, 3µl of the three different hybridization mixes were added (see 
Table 1 for all reaction mixes). Each mix contained the respective Salsa Probe mix for the 
detection of NB - P251, P252, and P253 – and was applied to only one of the three PCR 
tubes. The samples were first heated to 95°C for 1 minute and then the probes hybridized at 
60°C for at least 16 hours. Next, the samples were cooled to 54°C before applying 32μl of the 
Ligase-65 mix per tube. The ligation was then run for 15 minutes at 54°C before the ligase 
was inactivated and the DNA was denatured at 98°C for 1 minute. The samples were then 
kept at 10°C until further processing. In the meantime, fresh PCR tubes were prepared with 
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15μl of the PCR mix each. After the ligation program was finished, 5μl of the ligation 
reaction was transferred into the new PCR tubes. The PCR tubes were then put into the 
thermocycler and heated to 60°C before adding 5μl of the polymerase mix to each tube. The 
ligated probes were then amplified in 35 cycles of denaturing at 95°C for 30 seconds, 
annealing at 60°C for 30 seconds and elongation at 72°C for a minute. A final elongation step 
was afterwards performed at 72°C for 20 minutes before the program was put on hold at 
10°C. The samples were stored at 4°C until the next processing step. Separation of the 
amplified PCR products was done with capillary electrophoresis. A MicroAmp plate (Applied 
Biosystems, Darmstadt, Germany: Cat. No. N801-0560) was filled with 9.3μl of the 
electrophoresis mix per needed well and 1μl of the PCR product added before the wells were 
sealed. The samples were then analyzed with an ABI prism 3100 (Applied Biosystems). The 
data readout was interpreted with the MLPA Vizard software from the Austrian Research 
Center GmbH (Vienna, Austria). 
 
Name of Mix Component 1 reaction (µl) 
Hybridisation Mix Salsa Probe Mix 
MLPA Buffer 
1.5 
1.5 
Ligase-65 Mix Ligase-65 Buffer A 
Ligase-65 Buffer B 
Aqua dest. 
Ligase-65 
3 
3 
25 
1 
PCR Mix 10x Salsa PCR Buffer 
Aqua dest. 
2 
13 
Polymerase Mix Salsa PCR-primers 
Enzyme Dilution Buffer 
Aqua dest. 
Salsa Polymerase 
1 
1 
2.75 
0.25 
Electrophorese Mix Standard 500 Rox 
HiDi formamide 
0.3 
9 
Table 2: MLPA reaction mixes. Depending on the number of DNA samples the reaction mixes were done as 
master mixes. All reagents were obtained from MRC Holland except for aqua dest. and HiDi-formamide 
(Applied Biosystems, Darmstadt, Germany; Cat. No. P/N4311320C). 
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2.3.3 Single nucleotide polymorphism (SNP) array 
 
The Affymetrix GeneChip® Mapping 500K Assay was used in conjunction with the 
GeneChip® Mapping 500K set for the investigation of copy number alterations and 
segmental aberrations in the genome of hetMNA neuroblastoma. The protocol on the 
Affymetrix, Inc. (Santa Clara, CA, USA) support homepage 
(https://www.affymetrix.com/support/downloads/manuals/500k assay manual.pdf) was 
largely followed as instructed and reagents listed for the low throughput protocol were used. 
In short, approximately 250ng total genomic DNA was taken for each SNP array. The tumor 
DNA was digested with the restriction enzyme NspI before ligating the fragments to adaptors 
with a T4 DNA ligase. The ligation products were then amplified by PCR with generic 
primers recognizing the adaptor sequence. After purification of the PCR products, the 
amplified DNA was fragmented by DNaseI and labeled with biotin. The labeled DNA probes 
were hybridized to the NspI GeneChip® Mapping 250k array of the 500K array set. After 
hybridization, excess probes were washed from the arrays in an Affymetrix Fluidics Station 
450 and hybridized probes marked with streptavidin-phycoerythrin. The arrays were scanned 
using a confocal laser GeneChip Scanner 3000 (Affymetrix, Inc., Santa Clara, CA). In total, 
thirteen hetMNA NB tumor pieces from 5 patients were analyzed with the NspI 250K array.  
Data analysis was performed using the CNAG (Copy Number Analyzer for Affymetrix 
GeneChip Mapping arrays) software, version 3.0 (GenomeLaboratory, Tokyo University, 
http://www.genome.umin.jp) [116, 117]. The UCSC genome browser, assembly May 2004 
(http://genome.ucsc.edu/) was used to annotate and visualize regions of segmental 
chromosomal aberrations, gene amplifications and deletions. 
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2.4 Buffers and Solution 
 
1xPBS 
47,75g  PBS powder (Applichem, Darmstadt, Germany; Cat. No. A0964.9050) 
5l   deionized H20 
 
Eosin solution 
For 100ml working solution a 1:10 dilution of Eosin stock solution with deionized H2O as 
done with the addition of:  
5gtt 96% acetic acid (Merck, Darmstadt, Germanys; Cat. No. 1.00062.2511) 
5gtt 37%. Formaldehyde (Merck, Darmstadt, Germany; Cat. No. 1.04003.1000) 
 
3M Na-Ac 
2,46g   Na-Acetat (Merck, Darmstadt, Germany; Cat. No. TA636468) 
10ml   dH2O 
 
Master mix for nick translation 
500µl   Formamide (Merck, Darmstadt, Germany; Cat. No. 1.04003.1000) 
100µl   20x SCC (Applichem, Cat. No. A4506.5000) 
200µl   Dextransulfate  
200µl   dH2O 
 
Pepsin-containing solution 
0.5ml  HCl 
49.5ml   deionized H2O 
25µl  100mg/ml Pepsin (Sigma-Aldrich, Germany; Cat. No. P- 7012) 
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Erythrocyte- lysis buffer  
4,15g  NH4Cl 
0,5g  10mM KHCO3 
100µl  0,5M EDTA pH8.0 (Gibco, Auckland, New Zealand; Cat.No. P1513)  
500ml  deionized H2O 
 
Lysis buffer 
1,21g  Tris pH8.0 
23,376g  NaCl 
0,744g  EDTA 
 
TE buffer 
5ml    1M Tris pH7.6 or pH8.0 
1ml    0,5M EDTA 
494ml   deionized H2O 
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3 Results 
3.1 Detecting MYCN- heterogeneity in neuroblastoma  
3.1.1 Hematoxylin and Eosin stainings help in estimating tumor cell 
content but FISH is needed for detecting tumor heterogeneity 
 
In order to investigate the applicability of the histology-based, diagnostic workup of a 
heterogeneous NB tumor, we compared HE stainings to MYCN I-FISH-based detection of 
heterogeneity. Amplified tumor cells are generally identified by their MYCN- copy number 
with the respective FISH-probe according to the international consensus for neuroblastoma 
molecular diagnostics [115]. For the tumor to be categorized as “intratumoral heterogeneous”, 
surrounding non amplified cells also need to be identified as tumor cells which can be done 
by looking at the aneusomy of their chromosomes with specific FISH probes. In case of 
MYCN- amplified tumors, a probe to the centromere or the long arm of chromosome 2 is used 
as reference. HE stainings fail to show a clear difference in the morphology of MYCN- 
amplified and unamplified tumor cells within heterogeneous tumors and can thus not be used 
to identify heterogeneous tumors. On the other hand, information on the overall tissue 
morphology obtained by HE staining can be helpful for future tissue processing such as FISH 
stainings or microdissections. Figure 2A shows a picture of an area of a tissue section where 
tumor cells appeared well separated from one another and were thus accessible to the 
numerous reagents used during FISH staining. The area depicted in Figure 2B shows more 
fibrous stroma (Eosin pink) with embedded cells. These cells were generally less accessible 
for probe hybridization and needed a longer permeabilization or digestion in the FISH 
protocol. A longer digestion time, however, often led to the morphological destruction of 
more exposed nuclei. Stroma also showed a strong fluorescent background especially in the 
FITC- channel.  
Figure 2C features an in situ hybridization of FITC-labeled MYCN and Cy3-labeled D2Z 
probes. Disomic cells of unknown type (white arrows), which were potentially tumorigenic, 
and trisomic tumor cells (red arrow) were detected in the merged image with DAPI in the 
upper panel. A different staining with another NB marker is needed in addition to 
unequivocally identify the disomic cells as tumor cell. The lower panel features the same 
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staining of a different area with MYCN amplified (red arrow head) and non-amplified (red 
arrow) cells. In certain cases of NB, aneusomies and MYCN amplification can thus be 
detected with this combination of probes for chromosome 2. Since most NB are aneusomic 
for at least one chromosome, tumor cells can be easily differentiated from normal cells or 
from one another in case of heterogeneous tumors with the appropriate set of probes.  
 
 
Figure 2: Histopathological and interphase FISH stainings of tumor sections. All sections were cut at 5μm 
in a cryostat. (A) Histopathological HE staining of fibrous stroma-poor area of a NB section. (B) HE staining of 
a stroma-rich area of a tumor section. (C) FITC-, Cy3- and merged image with DAPI background of an area in a 
heterogeneous NB section. MYCN is green, D2Z red and DNA blue. White arrows mark disomic cells, red 
arrows mark tumor cell trisomic for chromosome 2 and the red arrow head a MYCN amplified cell. White bars, 
10µm. 
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3.1.2 Comparison of two-color MYCN I-FISH, MLPA and SNP array analysis 
for the detection of MYCN heterogeneity in neuroblastoma 
 
The international consensus for neuroblastoma molecular diagnostics set up by the INRG 
biology committee requests I-FISH for the unambiguous diagnosis of MYCN amplification in 
NB [115]. Furthermore, pan-genomic, DNA-based investigations, like MLPA, array CGH or 
SNP array analysis are commonly conducted to determine genetic aberrations and can usually 
also show MYCN amplification [118]. In this experiment, DNA and the corresponding tumor 
piece were used to compare MYCN I-FISH, MLPA and SNP array analysis in terms of 
sensitivity and accuracy in the detection of MYCN-amplified cells and genes comprised in the 
amplicon.  
For the mere detection of MYCN amplification by I-FISH, the MYCN probe was 
complemented by a reference probe for the centromeric region of chromosome 2 (D2Z) to 
illustrate the underlying chromosome copy number. A combination of probes to MYCN and 
adjacent genes NAG or DDX1 was applied to give a more detailed profile of the MYCN locus 
and to confirm potentially coamplified genes. In case of coamplification of a gene in the 
MYCN amplicon, the signal of its probe was expected to equal the number of MYCN signals in 
a cell. Fluorochromes FITC (green) and TRITC (red) were the used to immunofluorescently 
label MYCN and the reference probe, respectively, for fluorescence microscopy. 
Colocalization resulted in a yellow spot. Cells without MNA were expected to display the 
same number of colocalizations as the copy number of chromosome 2. In contrast to single-
cell detection with I-FISH, MLPA and SNP arrays are based on genomic DNA and designed 
to give an average copy number of sequence in the extracted tumoral DNA. Since multiple 
probes were simultaneously hybridized to cover a chromosome, aberrations of any kind were 
detectable on a larger genome basis. The MLPA kit employed in this experiment was custom-
designed with probes targeting a few preselected chromosomes of importance in NB 
detection. The 250k SNP array covered all chromosomes except the Y-chromosome with 
probes hybridizing to 250000 scattered single-nucleotide polymorphisms in the genome. 
SNPs were also used to investigate chromosomal copy numbers and genetic aberrations in the 
background of hetMNA tumors.  
The MLPA diagram in Figure 3A shows a clear amplification of the MYCN oncogene (red 
rectangle). The size of the amplicon was rather small and neither DDX1 nor NAG appeared 
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coamplified. The rest of the probes targeting chromosome 2 were rather uneven with a few 
outliers. Nonetheless, there was a good chance for an overrepresentation of the entire 
chromosome underlying MNA. The SNP array data in Figure 3B confirmed both MYCN 
amplification and the overrepresentation of chromosome 2. MYCN I-FISH data on this tumor 
corresponded well with MLPA and SNP array results. Although the nuclei contours were not 
always clearly separable, MYCN staining (green) and its reference signal from the centromeric 
D2Z probe (red) (Figure 3C) showed a clear imbalance in many cells. White arrows mark 
MYCN amplified cells in the figures. According to the INRG biology committee’s criteria 
[115], a large number of NB cells classified as MYCN-amplified. The copy number of the 
MYCN gene was more than fourfold in comparison to the centromeric reference probe. The 
assumption that DDX1 was not coamplified was verified by FISH results using MYCN and 
DDX1 probes in a two color FISH experiment (Figure 3D).  
However, the limitation of MLPA to detect rare amplified cells is shown with the tumor 
sample of Figure 4. The MLPA data showed a rather uniform overrepresentation of the entire 
chromosome 2, while an amplification of MYCN and genes surrounding the MYCN locus was 
not detected (Figure 4A). SNP arrays were also incapable of detecting a MYCN amplification 
but affirmed the overrepresentation of chromosome 2 (Figure 4B). On the contrary, I-FISH 
identified a number of tumor cells with increased copies of MYCN in comparison to the D2Z 
reference. Despite the fact that the contours of single nuclei were not always easy to 
determine, the number of MYCN signals clearly surpassed the two to three copies suggested 
by MLPA for the entire chromosome. White arrows mark amplified cells in the merged image 
of Figure 4C. Not only was the detection of rare cells carrying MYCN amplification 
unsuccessful by MLPA and SNP array but consequently the coamplification of NAG was 
missed as well (Figure 4D). 
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Figure 3: Comparison of MLPA and FISH results on MYCN amplicon detection and composition. 
Examination of a tumor DNA from patient #4 is done by MLPA (A) and SNP array analysis (B). The red 
rectangle in the MLPA readout of chromosome 2 marks the two MYCN probes. In the SNP array data, MYCN 
amplification is marked by the red arrow in the single-chromosome view of chromosome 2. The blue line 
illustrates the average copy number of both alleles; red (large) and green (small) lines depict allele based 
analyses. Chromosomes are represented by their cytoband information. Interphase fluorescent in situ 
hybridization (FISH) validates of MNA with MYCN (green) and D2Z (red) probes (C). Composition of the 
MYCN amplicon is confirmed with probes for MYCN (green) and DDX1 (red) (D). White arrows point out good 
examples of MYCN-amplified cells. White bar, 10µm. 
Due to the nature of the tissue, contours of single nuclei are again rather diffuse in large 
areas of the section. However, the density of characteristic yellow signals for colocalization of 
FITC- and Cy3-labeled FISH probes in areas of approximately the regular size of a nucleus 
were taken as a clear indication for coamplification of MYCN and NAG in this tumor sample. 
Non-MYCN-amplified nuclei also showed close proximity of probes for MYCN and NAG but 
only the two to three signals per nucleus which were expected from the MLPA and SNP array 
results.  
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Figure 4: MLPA and SNP array of a heterogeneous tumor do not always correlate with MYCN I-FISH 
results. Examination of a patient’s tumor DNA is done by MLPA (A) and SNP array analysis (B). The black 
rectangle in the MLPA readout of chromosome 2 frames the probes often comprised in a MYCN amplicon. The 
SNP array data is displayed in the single-chromosome view of chromosome 2. The blue line illustrates the 
average copy number of both alleles; red (large) and green (small) lines depict allele based analyses. 
Chromosomes are represented by their cytoband information. Interphase fluorescent in situ hybridization (FISH) 
validates of MNA with MYCN (green) and D2Z (red) probes (C). Composition of the MYCN amplicon is 
examined with probes for MYCN (green) and NAG (red) (D). White arrows point out good examples of MYCN-
amplified cells. White bar, 10µm. 
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3.1.3 Intratumoral heterogeneity in MYCN amplicon composition  
 
Heterogeneity in MYCN amplicon size and composition has thus far not been reported in 
the same piece of a heterogeneous MNA neuroblastoma. The genetic composition of the 
MYCN amplicon was investigated by I-FISH with probes to MYCN and the adjacent gene 
DDX1. MLPA and SNP array data was again consulted for comparative reason. Data of the 
tumor presented in Figure 5 strongly indicates the existence of tumor cells carrying different 
MYCN amplicons in the same tumor piece. MLPA data revealed a large MYCN amplicon 
including DDX1 and parts of NAG as well as an overrepresentation of the entire chromosome 
2. SNP array data of the same tumor DNA confirmed the gain of chromosome 2 and clearly 
illustrated the MYCN amplification (Figure 5B). The detected amplicon appeared rather large 
spanning the 2p24.32p34.1 region with a size of approximately 8Mbp. Sequence analysis 
with the USCS genome browser (hg17) suggested the inclusion of MYCN-adjacent genes like 
NAG, DDX1,SMC6, and SDC1 in the amplicon which have been reported to be coamplified in 
a core region identified in a number of MNA neuroblastoma [42]. While the average of both 
alleles (blue graph) portended a plateau similar to the MLPA data, a higher peak in the larger, 
red allele was identified which corresponded to MYCN specifically (Figure 5B, red arrow). 
Amplicon composition was further investigated by MYCN/DDX1 I-FISH and confirmed the 
existence of tumor cells with the two amplicons in the same tumor piece (Figure 5 C). Tumor 
cells in the upper panel of Figure 5C carrying MYCN/DDX1 coamplifications are marked with 
white arrows and contrasted the marked tumor cell with a “MYCN-only” amplicon in the 
lower panel. Although the definition of the border of the marked nucleus in the lower panel is 
again difficult, a clear imbalance with an estimated ratio of 16/5 between MYCN and DDX1 
signals is visible. The five DDX1 signals show good correlation to MYCN probes and 
correspond well to the copy number of chromosome 2. Coamplification of the other, adjacent 
genes was not examined by I-FISH. 
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Figure 5: Heterogeneity in size and composition of the MYCN amplicon in a hetMNA neuroblastoma. (A) 
MLPA data of chromosome 2 shown with a red rectangle marking the amplified genes. In the single-
chromosome view of SNP array data on chromosome 2 is displayed (B). The large amplicon in marked by the 
black bar and the MYCN-only amplification by the red arrow. The blue line illustrates the average copy number 
of both alleles; red (large) and green (small) lines depict allele based analyses. Chromosomes are represented by 
their cytoband information. (C) I-FISH stainings with probes for MYCN (green) and DDX1 (red) were applied to 
illustrate the heterogeneous amplicon structure. DDX1-coamplified tumor cells are marked by white arrows in 
the upper panel. A cell carrying the “MYCN-only” amplicon is pictured in the lower panel. White bars, 10µm.  
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3.2 Genetic heterogeneity in hetMNA neuroblastoma  
 
The role of the genetic background in the initiation of MYCN amplification in NB has in 
the past not been sufficiently studied and was examined only partially in homogenously 
MYCN-amplified neuroblastoma [12]. To investigate whether a common segmental or 
chromosomal aberration in the tumor background is underlying the initiation of MYCN 
amplification can best be studied in hetMNA NB. For this purpose, we examined tumors with 
a varying number of MNA tumor cells in focal areas or scattered among unamplified tumor 
cells. In total, five patients with hetMNA were included in this study. According to the work 
up protocol of the INRG biology group [115], MNA was confirmed by MYCN I-FISH in at 
least one tumor piece of each patient. SNP arrays were selected to investigate chromosomal 
copy number alterations in a total of 13 tumor pieces. The following data focuses on the 
difference of segmental chromosomal aberrations, deletions and amplifications between 
tumor pieces and only partially at numerical chromosomal differences.  
The standard genomic overview as obtained by the SNP array read-out and subsequent 
analysis with the CNAG software is shown for patient #1 in Figure 6. Heterogeneity for MNA 
was already visualized with MYCN I-FISH. The majority of NB cells showed no amplification 
while approximately one per cent of scattered tumor cells had MNA of up to 15-fold in 
reference to the copy number of chromosome 2. Since there was only one tumor piece of the 
patient available, investigation of heterogeneity was only possible within this piece. The DNA 
index for the tumor cells was not determined. Since CNAG draws the base line according to 
average copy number, the inference to tumor ploidy was difficult without other leads. Routine 
I-FISH stainings clarified the copy number of at least a few chromosomes. The application of 
the centromeric probe D1Z1 and the 1p subtelomeric probe D1Z2 showed cells with up to six 
balanced signals for both probes suggesting an average hexasomy for chromosome 1. Non-
amplified tumor nuclei showed a balance of up to 8 copies of both arms of chromosome 2. 
Testing for chromosome 17 aberrations with probes for both p- and q-arm proved a 
predominantly unbalanced ratio with 4/5 and 6/7 signals per cell suggesting a potential 17p-
deletion or 17q-gain. Based on the FISH data, we decided that the zero-line in the SNP array 
results corresponded to 6 copies of a chromosome. Another challenge in SNP array based 
analysis of heterogeneous tumors is the identification of different tumor cell clones with 
different single chromosome copy numbers and ploidies that contribute DNA according to 
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their percentages of the entire cell population. Our SNP arrays were limited to showing an 
average chromosomal copy number of the tumor cell population. Thus, the MYCN 
amplification (Figure 6, red arrow) was only vaguely visible in the analysis due to a low 
percentage of MNA tumor cells. It was also apparent that cells existed which carry a 2p-gain. 
Whether MYCN amplification and 2p-gain occurred in the same cell was not possible to be 
clarified satisfyingly. Furthermore, chromosome 4 showed two gains, the first at the telomere 
of the p-arm (4pter4p16.1) and the second close to the centromere on the q-arm 
(4q114q12), as well as an amplification corresponding to CXX4 gene (blue asterisk). This 
gene is a negative regulator of the Wnt signaling pathway. Chromosome 6 had two break 
points, the first one at 6q12 and the second at 6q15. While 6pter6q12 including the 
centromere was on average septa- to octasomic, the part between 6q12 to the second break 
point at 6q15 was only hexasomic. The region 6q156qter was even tetrasomic.  
 
 
Figure 6: All genome view of SNP array data provided an excellent overview of genomic aberrations in 
tumor samples. SNP array data from patient #1 is shown in the all-genome-view generated. The blue line 
illustrates the average copy number of both alleles; red (large) and green (small) lines depict allele based 
analyses. Chromosomes are represented by cytobands information. The red arrow points at the MYCN-location 
on chromosome 2, while black arrows mark chromosomal break points and asterisks other amplifications. For 
better visualization of segmental aberrations, gains are highlighted in transparent red and losses in transparent 
green.  
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Chromosome 12 appeared to be tetra- to pentasomic but two regions were displayed with 
very strong hybridization signals indicative of amplified sequences. These regions flank a 
fragment which was completely lost in the smaller allele and showed reduced hybridization in 
at least two copies of the 3 to 4 copies of the larger allele. Interestingly, the more terminal 
amplicon included the Mdm2 gene locus at 12q15. Mdm2 is proven to be an important 
repressor of the transcriptional activity of the p53 tumor suppressor and induces p53 
degradation [119]. Whether these amplifications and the loss were actual genomic alterations 
remains to be tested by FISH with appropriate DNA probes or other methods. A partial loss of 
the p-arm of chromosome 17 was also detected with a break point at 17p12. It is clearly 
visible that only the smaller, green allele was affected by the loss of the fragment 
17pter17p12. The larger, red allele remained intact leading to an overall ratio of 
approximately six copies of the 17p-arm versus eight copies of the rest of the chromosome. 
When compared to the 17p/q- I- FISH results, the assessment of the ratio seemed to be 
accurate. 
Touch preparations were sent in for routine FISH diagnostics of the tumor of patient #2. 
Two distinct areas were identified with MNA NB cells, a large area with 5000 cells and an 
estimated percentage of 30-40% MNA tumor cells and a smaller area of 2000 cells and 
roughly 10% MNA. The copy number of MYCN was increased of up to 20-fold in reference to 
the largely trisomic chromosome 2. Few, diffuse MNA cells were also found in close 
proximity to the two focal areas. Touch preparations and cryosections from four tumor pieces 
labeled A to D also showed on average tri- to pentasomies for chromosome 2 but no MNA 
cells were detectable by MYCN-FISH (data not shown). Correspondingly, none of the tumor 
pieces revealed MYCN amplification in SNP array analysis (Figure 7). While tumor pieces A 
to C only showed numerical aberrations, tumor piece D additionally presented a 
17pter17p11.2 deletion. The break appears to have occurred with higher incidence in the 
larger, red allele, and only to a minor extend in the smaller, green allele of a few tumor cells.  
On average, all four pieces were pentasomic for chromosome 17 with tumor D having lost 
the terminal region of the 17p-arm. Furthermore, SNP array data confirmed disomy of 
chromosome 11 but tumor piece C showed a uniparental isodisomy with the small allele 
entirely lost and the other one duplicated (data not shown) adding another level of 
heterogeneity to the tumor of patient #2. The unmarked deletion visible in pieces B to D was 
likely an artifact from the procedure with no known gene sequence affected.  
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Figure 7: One out of four tumor pieces from patient #2 showed a 17p- deletion. SNP array analysis was 
done on the four tumor pieces of patient #2 labeled A to D. Chromosome 17 is shown in the single-chromosome-
view. The blue line illustrates the average copy number of both alleles; red (large) and green (small) lines depict 
allele based analyses. The chromosome is represented by the cytoband information. For better visualization of 
the 17p segmental aberrations, the loss is highlighted in transparent green and the black arrow marks the break 
point.  
 
The molecular-cytogenetic I-FISH report for patient #3 was based on two pieces A and B 
of the same tumor. The report stated that MNA was only detected in tumor piece B with 
numerous cells carrying a 15- to 30-fold increased copy number of MYCN. Piece A and a 
biopsy, which was sent a week in advance of the tumor, did not confirm the existence of 
MNA. However, tumor piece A was later sectioned again for the investigation of 
heterogeneity in MYCN amplicon composition by FISH and eventually revealed MNA in a 
few scattered cells. MNA heterogeneity was thus already visible in the FISH results from both 
tumors. SNP array analysis confirmed the heterogeneity. With a DNA index of 1.55, both 
tumor pieces showed the same extensive numeric chromosomal aberrations (NCA) including 
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a trisomy of chromosome 2 which is visible in Figure 8. Segmental chromosomal aberrations 
at the applied array resolution were not detected. The MYCN amplicon was only detectable in 
tumor piece B owing to the high percentage of MNA NB cells in the B piece. The size of the 
amplicon was rather large spanning the 8Mbp region 2p24.32p34.1 and included adjacent 
genes like NAG, DDX1,SMC6, and SDC1 which were shown to be coamplified in a core 
region of a number of MNA NB tumors [42]. Interestingly, a higher peak in the larger, red 
allele was identified which corresponded to MYCN specifically. The detection of the peak and 
the plateau in the same tumor piece suggested amplicon heterogeneity with a small, MYCN- 
only besides the large amplicon containing the coamplified genes listed above. Amplicon 
composition was investigated by MYCN/DDX1 I-FISH and confirmed the existence of tumor 
cells with the two amplicons (Figure 5). Coamplification of the other, adjacent genes was not 
examined by I-FISH. 
 
 
Figure 8: MNA heterogeneity was detected in the two tumor pieces of patient #3. Pieces A and B were 
screened for chromosomal aberrations with SNP arrays. The single chromosome views are shown in the black 
boxes for chromosome 2. The MYCN amplicon is marked by a black bar and the location of MYCN gene 
indicated by the red arrow. The blue line illustrates the average copy number of both alleles; red (large) and 
green (small) lines depict allele based analyses. The chromosome is represented by its cytoband information. 
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Four tumor pieces labeled I to IV were screened of patient #4. Each of the touch 
preparations that were used for I-FISH routine diagnostics of the four pieces revealed MNA 
tumor cells. While the touch preparations of pieces II to IV only showed a sparse number of 
diffuse amplified cells, tumor piece I revealed focal cells with a two to 15-fold increase of 
MYCN in reference to a tri- to tetrasomic chromosome 2. Furthermore, I-FISH with probes 
D1Z1 and D1Z2 proved segmental imbalance for chromosome 1, which suggested a 1p 
deletion in the majority of tumor cells of pieces II and IV and to a lesser degree in the touch 
preparation III. Tumor cells from piece I, on the other hand, appeared balanced for both 
probes. The patient report also mentioned the non-existence of a segmental aberration of the 
tetrasomic chromosome 17. SNP array analysis of the four tumor pieces confirmed to a large 
extent the patient report (Figure 9). Tumor piece I was the only one with a detectable MYCN 
amplification, while the other pieces showed no sign of amplification due to the low 
abundance of MNA tumor cells. On the contrary to the patient’s FISH report, the 1p loss was 
not only visible in three but in all four pieces. The aberration was most prominent and clear 
cut in tumors II and IV. Breakpoints in pieces I and III were less clear to identify and the 
aberrations were less defined indicating a low percentage of 1p-aberrated cells. Interestingly, 
the 1p-aberrations were of different size in the tumor pieces. At least two distinct breaks were 
detectable. While tumor cells in piece II carried a 1pter1p22.2 loss, NB cells in piece IV 
showed a 1pter1p21.2 loss. The other two pieces potentially shared both clones in low and 
different quantity which might explain the smooth decrease in signal and the more difficult 
identification of the actual chromosomal break point. Data to confirm this assumption was not 
collected. Furthermore, data for chromosome 3 of tumor II indicated a segmental gain of the 
region 3q13.313qter which likely affected both alleles. A comparable gain was not 
identified in the other three tumor pieces. Additionally, an 11q-loss of primarily the larger 
allele was detected in piece IV and unmatched in the other pieces. Numeric chromosomal 
aberrations for a number of chromosomes were also detected and were consistent in all four 
pieces. According to I-FISH data, tumor piece IV was tetrasomic for chromosome 1 while the 
other pieces were trisomic (data not shown). 
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Figure 9: Four tumor pieces of patient #4 revealed extensive genetic heterogeneity. SNP array data of 
patient #4 is shown in an overview of selected single-chromosome-views generated with the CNAG 3.0 
software. Chromosomes 1, 2, 3 and 11 were selected because of heterogeneous genetic aberrations. The blue line 
illustrates the average copy number of both alleles; red (large) and green (small) lines depict allele based 
analyses. Chromosomes are represented by their cytoband information. The red arrow points out the genomic 
MYCN location, while black arrows mark chromosomal break points. For better visualization of segmental 
aberrations, gains are highlighted in transparent red and losses in transparent green. 
 
The case of patient #5 was different from the other four patients. Two different tumor 
pieces were screened for heterogeneity, the initial tumor and a resection during treatment 
(D.T.). The patient report of the near-triploid initial tumor with a DNA index of 1.49 included 
the detection of a 1p-deletion, three centromeres versus one or two p-telomeres, by FISH in 
the majority of tumor cells interspersed with a few cells without deletion. In the respective 
touch preparation of the tumor, very few cells (~0.05%) were identified by I-FISH to carry an 
MYCN amplification of up to 30-fold. An aberration of chromosome 17 was not detected. 
PCR was used for the investigation of the loss of heterozygosity of chromosomal region 
1p36.6 in the D.T. - tumor and did not confirm the loss detected in the initial tumor. MNA 
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was also not detectable by southern blot analysis with a pNb1 probe. MYCN I-FISH was not 
conducted on this piece. 
SNP array data on both tumors revealed contradictory results to the FISH report (Figure 
10). Heterogeneity of MNA was verified, but not as suggested by the molecular-cytogenetic 
report. While in the initial tumor MNA was absent on the SNP array, a clear peak was 
detected in the D.T. - tumor piece. Additionally, the 1p segmental loss seen by I- FISH in the 
majority of cells in the initial tumor was not confirmed by SNP array. Both tumors displayed 
a gain of a ~1000kb region (17q21.3117q21.32) on chromosome 17. Among other genes, 
this segment includes WNT3 and WNT9B which are two genes of the WNT gene family and 
are implicated in oncogenesis [120]. The gain also included MAPT, a gene with common 
numeric variants (CNV) in humans. A consistent deletion was also detected at 20p12.1 on 
chromosome 20 but did not include a known gene. This site was also compared to the UCSC 
data base of genomic variants and was identified as a CNV as well. Reference material from 
the patient was not tested to differentiate between CNV- or tumor-specificity. 
 
 
Figure 10: Heterogeneity of MNA was detectable in the initial tumor and in the resected tumor during 
treatment. The two pieces of patient #5 were screened for chromosomal aberrations with SNP arrays. Single-
chromosome-views are shown for chromosome 2, 17, and 20. The MYCN amplicon is indicated by a red arrow. 
The amplification on chromosome 17 is marked with a blue arrow and the deletion on chromosome 20 with a 
green arrow. The blue line illustrates the average copy number of both alleles; red (large) and green (small) lines 
depict allele based analyses. The chromosome is represented by its cytoband. 
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An overview of the SNP array data of each of the 13 tumor pieces is given in Figure 11. 
Since all tumors were at least near-triploid, every sample carried a number of whole 
chromosomal gains marked by the light pink color. Except in the potentially hexaploid tumor 
of patient #1, chromosome 19 was the only chromosome which appeared disomic. 
Chromosomes 1, 2, 5, 6, 7, 8, 12, 13, 17, 18, and 22 were all overrepresented in the 13 tumor 
pieces. A common segmental aberration, however, was not identified at the resolution of the 
applied SNP arrays and is thus unlikely to initiate MYCN amplification. Due to the 
heterogeneity of the tumor cells in the pieces used for DNA extraction and the nature of SNP 
arrays, a conclusion on potential combinations of certain aberrations in a single cell cannot be 
drawn. 
 
Figure 11: Heterogeneous tumors show no common segmental aberration. Affymetrix GeneChip® Human 
Mapping 250K Nsp Arrays were used to investigate the genetic background of hetMNA NB. The different tumor 
samples were compared to one another. The light pink color marks entire overrepresented chromosomes, light 
red depicts gained segmental aberrations and dark green lost segmental aberrations. The dark red bands illustrate 
amplifications and green bands deletions. The bands for the MYCN amplicon and other single-gene aberrations 
are slightly broadened for better visualization and do not resemble the actual size of the amplicon. Since the 
analysis of the array data is based on a diploid karyotype, white color indicates disomic chromosomes. * The 
tumor of patient #1 showed strong heterogeneity in the MYCN I-FISH results. ** The two compared tumor 
pieces of patient #5 were primary and during-therapy. Pat. # patient number; Tu. # tumor number: In initial: D.T. 
during therapy 
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3.3 Genetic instability involvement in MYCN- amplification 
 
DNA double strand breaks were reported to lie at the bottom of gene amplification [121]. 
However, the role of DSBs in the establishment of MYCN amplification in NB tumors has so 
far not been clarified sufficiently. In these experiments, we conducted first steps to examine 
whether DSBs are underlying amplification of MYCN. By immunofluorescence detection of 
γH2AX at the loci of DSBs and subsequent MYCN I-FISH, we investigated the correlation of 
unrepaired DSBs and MYCN amplification on sections of NB tumors. Our prime interest lay 
in heterogeneous tumors which are best-suited to discriminate DSB-occurrence in MYCN 
amplified from non-amplified tumor cells in the same tissue section. As references, we 
included homogeneous neuroblastoma in our study that showed NCAs-only, no MNA but 
SCAs and NCAs and tumors with classic MNA and SCAs in their MLPA analysis.  
The staining pattern of γH2AX on hetMNA tumor cryosections revealed an overall 
independence of MYCN amplification and the presence of DNA double strand breaks in the 
same tumor cell (Figure 12). Two tumor pieces of a patient’s neuroblastoma (Figure 12A and 
B) were chosen that revealed only numeric chromosomal aberrations in the background of a 
MYCN amplification in the one tumor piece (Figure 12B) by MLPA and SNP array analysis 
(see also Figure 8 for excerpts of the SNP array data). Frozen sections of both pieces 
generally displayed a diffuse γH2AX staining in a few tumor cells which varied from a very 
weak pan-nuclear staining to a strong granular staining with some distinct foci. For one, the 
displayed images give the impression that the γH2AX staining pattern is unclear and the 
occurrence of DSBs is neither connected to tumor cells carrying NCAs with normal MYCN 
copy number (red arrows) or with amplification( red arrow heads). Furthermore, tumor cells 
of both types were detected without any γH2AX staining (white arrow). It also appeared as if 
most MYCN amplified tumor cells displayed only a very weak signal or were even negative 
for γH2AX.  
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Figure 12: MYCN amplification only partially correlates with the occurrence of DNA double strand 
breaks in hetMNA neuroblastoma. Images show combined stainings of FITC-labeled MYCN I-FISH (left 
column) on Cy3-labeled γH2AX prestained cryosections (middle column) of hetMNA tumor pieces. Merged 
images of FITC, Cy3 and DAPI are depicted in the right column. Stainings of two tumor pieces of the same 
hetMNA neuroblastoma with NCA are displayed; one piece with a very low percentage or no MNA cells (A), 
the other with a high percentage of MNA cells (B). Two pieces of a hetMNA tumor with SCA are depicted in the 
lower two rows, one with no detectable MNA cells (C) the other with large areas of amplified cells (D). White 
arrows point at tumor cells with little or no γH2AX staining, red arrows at tumor cells with γH2AX staining, the 
arrow heads at double-positives, and the green arrow at a disomic cell of unknown cell type. White bar, 10µm. 
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The two lower panels of Figure 12 feature stainings of a hetMNA tumor with segmental 
chromosomal aberrations (see also Figure 9 for excerpts of the SNP array data). The section 
in Figure 12C of the MNA-poor tumor piece displays a number of tumor cells without MYCN 
amplification that presented γH2AX foci (red arrow) in close proximity to negative cells 
(white arrow). Foci were also detected in disomic cells of unknown type (green arrow). The 
MNA-rich tumor piece (D) was almost devoid of γH2AX-positive cells with a few exceptions 
that exhibited a pan-nuclear staining (D, red arrow and red arrow heads). However, the 
majority of MYCN-amplified tumor cells were negative for the phospho-histone staining.  
In order to obtain an impression of the overall genomic instability and the incidences of 
γH2AX-positive cells in a tumor, single images were stitched together to a section overview. 
Figure 13 displays the two previous heterogeneous neuroblastomas (Figure 13A/B and C/D) 
in comparison to homogeneous neuroblastoma reference material (Figure 13E/F, G/H and I/J). 
As aforementioned, the homogeneous tumors were assigned to three different categories: 
NCAs-only, NCAs and additional SCAs, and classic MNAs with segmental and numeric 
chromosomal aberrations. At least three tumors of each category were examined for their 
γH2AX staining pattern. The selected hetMNA tumor pieces both featured high frequencies of 
MYCN amplified cells detected by I-FISH. MNA was also traceable in each case by MLPA 
and SNP array analysis (see also Figure 5 and Figure 3). The hetMNA tumor with only NCAs 
in the genetic background of MNA (A/B) demonstrated a heterogeneous staining pattern with 
a higher number of γH2AX- positive cells in comparison to the tumor with additional SCAs 
(C/D). Although a few cells displayed a stronger granulation (B), the overall staining in the 
two selected pieces was diffuse and occasionally pan-nuclear. In the tumor representing 
neuroblastoma with NCAs-only, very few cells stained for γH2AX (E/F). Additionally, a 
number of these cells were of unidentifiable cell type and proved to be disomic for MYCN (F, 
green arrow). Neuroblastoma with segmental aberrations displayed a more extensive staining 
pattern. Again, tumor cells were either negative or positive for γH2AX and some cells of 
potential stromal character also exhibited the staining. While the difference in the overall 
intensity of the γH2AX staining between tumors with NCA-only and those with segmental 
aberrations was not always striking, “classic” MNA neuroblastoma always presented a 
discriminable, unique staining. A high number of MYCN amplified cells showed a cloudy, 
diffuse γH2AX staining largely different from cells of the other tumor categories. A few 
amplified cells evidenced a very strong pan-nuclear staining (Figure 14).  
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Figure 13: γH2AX staining pattern is heterogeneous in different hetMNA neuroblastoma and compares 
weakly to homogeneous tumors. Overview images and the detailed images in the panel below are always from 
the same tumor. Overviews are stained for γH2AX and counterstained with DAPI. In the panel of the detailed 
images, MYCN- FISH is green (left image), γH2AX immunostaining is red (middle image). Merged images 
(right image) are counterstained with DAPI (blue). Correlated stainings are displayed for γH2AX and MYCN 
amplification in a hetMNA tumor with NCA (A) and a hetMNA tumor carrying SCAs (B). References of MYCN 
I-FISH and γH2AX immunostaining on sections of homogeneous NBs with NCA without MNA (C), SCAs 
without MNA (D) and SCAs with classic MNA (E) are given below. Red arrows denote positive and white 
arrows negative tumor cells for γH2AX staining. Red arrow heads identify double-positive cells. The green 
arrow marks a γH2AX positive cell of unknown cell type. White bars, 10µm. 
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Interestingly, the “classic” MNA tumors also showed an overall heterogeneous γH2AX 
staining pattern with focal areas with a majority of positive tumor cells and areas completely 
devoid of or with only single positive cells Figure 14.  
 
 
Figure 14: “Classic” MNA neuroblastoma display areas without and with strong γH2AX immunostaining. 
Images show combined stainings of FITC-labeled MYCN I-FISH (left column) on Cy3-labeled γH2AX 
prestained cryosections (middle column) of MNA tumor pieces. Merged images of FITC, Cy3 and DAPI are 
depicted in the right column. Red arrows mark tumor cells with strong γH2AX positivity. Images were taken at 
40-fold magnification with fixed integration times. White bar, 10µm. 
 
One of the examined tumors with SCAs carried a loss of distal 11q which was detected by 
MLPA (Figure 15). Based on the MLPA readout (Figure 15A), it can be said that at least a 
segment starting with the gene CNTN5 at 11q22.1 to THY1 at 11q23.3, possibly to the 
terminus of chromosome 11, was continuously lost in this tumor. Although the MLPA kit 
lacks probes for the H2AFX gene locus at 11q23.3 specifically, it can be assumed by the 
losses of the proximal gene HMBS and the distal gene THY1 that H2AFX was also lost. The 
ATM gene, which encodes the ATM kinase that phosphorylates H2AX upon DNA double 
strand break recognition, was additionally included in the lost segment. Nonetheless, the 
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tumor displayed γH2AX-specific staining in a number of cells (Figure 15B/C). The type of 
these cells, however, remained unclear since most of them proved to be disomic in MYCN I-
FISH and were thus not unambiguously identified as tumorigenic (red arrows). Well-defined 
trisomic cells, on the other side, stained largely negative (white arrows). Despite the 
segmental loss of 11q, a number of cells show no implication on DNA double strand break 
signaling or repair. However, an additional neuroblastoma-specific staining needs to be 
conducted to clarify the nature of theses γH2AX-positive cells. 
 
 
Figure 15: Neuroblastoma with 11q-loss shows substantial γH2AX staining. MLPA displays prominent 11q 
deletion including the H2AFX gene locus (A). The detailed images (B) in the panel below and part of section 
overview (C) are from the same tumor. MYCN- FISH is green, γH2AX immunostaining is red and DNA is blue 
for all images. Images were taken at 40-fold magnification with fixed integration times and stitched together for 
the overview. Black rectangle marks the lost segment on chromosome 11. White arrows mark examples of 
γH2AX negative tumor cells and green arrows positive cell of unknown cell type. White bar, 10µm. 
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4 Discussion 
 
The accurate categorization of neuroblastoma is a crucial step in the decision making 
process for the appropriate treatment approach for a patient. Treatment strata are increasingly 
sharper formulated for homogenous NB [122]. The risk stratification for a potential outcome 
of this subgroup is more predictable. Up to this point, the clinical relevance of heterogeneity 
in NB remains largely non-elucidated and the tumors are difficult to assign to specific risk 
groups and outcome. Amplification of the MYCN oncogene is one of the standing markers for 
the detection and diagnosis of an aggressive subset of neuroblastoma with dismal prognosis 
[9, 17, 123]. Contradictory results were recently published on the ability to determine tumor 
progression of a few MNA cells [48]. On the other side, MNA in homogeneously amplified 
tumors is considered to induce rapid tumor progression possibly contributing to metastatic 
growth. A major area of uncertainty in homogenous as well as heterogeneous MNA 
neuroblastoma is the emergence of MYCN-amplification in tumor. While the actual event of 
amplification is regarded to occur in a episomal model [40 (in press)], the elicitor has not been 
found yet.  
 
 
4.1 Detecting heterogeneity in neuroblastoma 
 
In this report, we assessed the performance of different techniques in the identification of 
MYCN amplification in hetMNA tumors. Knowing the tumor cell content in a patient sample 
is crucial for the correct interpretation of results obtained by methods other then single-cell 
approaches. DNA, RNA or protein extraction is the initial step for PCR or array-based 
examination of samples. Without selection of specific areas by microdissection, for instance, a 
large number of cells is generally processed which leads in subsequent molecular tests to 
averaged results for a cell population. There is also a good chance that a high percentage of 
non-tumor cells can distort the data and identification of the genetics of a tumor clone can be 
complicated or even impossible. Assessment of tumor material is usually done with a 
pathologist on the grounds of hematoxylin and eosin stainings of sections. Additionally, the 
International Neuroblastoma Risk Grouping (INRG) biology committee allows the estimate of 
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tumor cell number to be based on I-FISH in certain NB cases [115]. Furthermore, the 
committee has set the required tumor cell content to more than 60% for most molecular 
studies and to more than 20% for ploidy measurement. BAC probes are generally used to 
investigate numeric aberrations of chromosomes, which are characteristic for a wide range of 
NB. 
Our results on a total of 13 hetMNA tumor pieces from 5 patients confirmed that the 
histological workup of a tumor sample, the way it is done by pathologists with hematoxylin 
and eosin staining, is not sufficient to detect MYCN heterogeneity in NB. Morphologically, 
there is frequently no visible difference between homogeneous and heterogeneous tumor cells 
within the same tumor. MYCN- FISH is the only method for detecting amplification on a 
cellular basis and can lead to the confirmation of MYCN copy number heterogeneity already 
by itself. I-FISH with probes for the two respective chromosome arms can furthermore 
visualize a different form of heterogeneity by detecting segmental and numerical aberrations 
in tumor cells. In addition, MLPA is routinely performed on tumor DNA since a good 
overview of all relevant aberrations in NB can be obtained rather quickly. We also included 
SNP array-based analysis of the same DNA pool in our comparison. Our results clearly prove 
an advantage of I-FISH over both other methods in terms of detecting heterogeneous MNA. 
Since MLPA and SNP arrays are based on DNA analysis of many thousand tumor cells, the 
results only depict the average cell. As soon as the percentage of MYCN amplified cells is 
below a certain threshold – 60% is the threshold for tumor cells versus normal tissue – and the 
MYCN copy number per cell is rather low, a detection of MNA in the background of other 
tumor cells is impossible. MYCN I-FISH combined with a reference probe like D2Z showed 
the required sensitivity to detect single amplification events in well-permeabilized tumor 
cryosections. On the downside FISH is more time- and money- consuming and thus not suited 
to study the genetic background in detail in a hetMNA NB. However, we can confirm that the 
demand of the INRG Biology Committee to conduct MYCN I-FISH applies to heterogeneous 
MNA tumors and is absolutely necessary for single cell detection [115]. Genomic approaches 
like MLPA or array-based techniques are not sufficient to diagnose hetMNA NB and need to 
be combined with MYCN I-FISH. 
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4.2 Heterogeneity in amplicon composition  
 
As aforementioned, genetic heterogeneity in neuroblastoma can assume different 
manifestations and heterogeneous MYCN amplification is one of them. Another form of is the 
number of amplicons per tumor cell. Episomal amplification of NUP214-ABL1 fusion gene in 
T- cell acute lymphoblastic leukemia (T-ALL) confers oncogenicity similar MYCN in 
neuroblastoma [124]. Due to the absence of a centromeric structure, the episome segregates 
unequally during mitosis and establishes a heterogeneous pattern in the tumor cells [36, 124]. 
Analogously, the MYCN amplicon in NB has also been observed to divide disproportionally 
during cell division. Whether this imbalance in amplicon number has any relevance for 
progression and prognosis of the tumor cannot be said.  
Reports on heterogeneity in amplicon composition in the same NB tumor piece have not 
been published to our best knowledge. However, our data strongly supports the presence of 
different amplicons in the same hetMNA NB tumor (Figure 5). According to the detected 
amplicon size by MLPA, the majority of tumor cells showed a clear DDX1 coamplification. 
Additionally, single cells were found to display a clear imbalance of signals for MYCN and 
DDX1 suggesting a smaller amplicon without coamplifications of the DDX1 gene. 
Interestingly, the two amplicons were also picked up by SNP array analysis in form of a 
plateau for the larger amplicon and a smaller, higher peak encompassing only the MYCN 
locus in one of the alleles. At the moment, we can only speculate about the emergence of the 
two different amplicon compositions. The coamplification pattern in a MYCN amplicon has 
shown extraordinary resistance to variability even during and after therapy [125]. However, 
an evolution of the MYCN amplicon cannot be dismissed per se. Since the most selective 
pressure is on the MYCN oncogene itself, a loss of the other genes in the amplicon would not 
lead to a disadvantage in proliferation and survival of the cells. Hence, a rearrangement is 
certainly possible. Another explanation would be the induction of MYCN amplification in two 
distinct cells of the same heterogeneous tumor. Whether it is assumed that either hetMNA 
neuroblastomas have a certain proneness to MYCN amplification or initiation is a result of 
chance, the possibility that two different amplicons can arise independently in the same tumor 
exists. 
 
57 
 
4.3 Genetic background in hetMNA neuroblastoma 
 
HetMNA neuroblastomas are an exceptional subgroup of MYCN- amplified tumors given 
that MNA tumor cells often compose only the minority of cells in these tumors. The majority 
of tumor cells show no amplification. MYCN-amplified NB cells are not considered to 
proliferate slower than the other tumor cells. Therefore, we can assume that unamplified 
tumor cells emerged earlier than the MYCN-amplified ones giving rise to the different 
population sizes. Furthermore, we identified different amplicon compositions in the same NB 
tumor. Hence, we hypothesized that hetMNA NB tumors are prone to develop MYCN 
amplification and can do so independently in different tumor cells. To find support for this 
theory, we focused on chromosomal aberrations in the genomic background as potential 
triggers for MNA and looked for congruence in heterogeneous tumors of five different NB 
patients. We applied 250K SNP arrays in our investigation of a total of 13 tumor pieces.  
Numerous chromosomes were mutually overrepresented in their entireness in all 13 tumor 
samples, which was expected since the tumors were at least near-triploid. Except in a near-
hexaploid tumor, chromosome 19 appeared disomic in the other four tumors. To our 
knowledge, whole chromosome 19 underrepresentation has not been linked to tumorigenesis 
in cancer. Any relevance is difficult to imagine since this chromosome was disomic. A 
common segmental aberration, however, was not detectable at the resolution of the applied 
SNP arrays and can thus be excluded as a sole initiator of MNA. The fact that MNA occurs 
independently from a specific larger segmental aberration in heterogeneous tumors can 
already be concluded from the SNP array profiles of tumor pieces of two patients. While 
distinctive MYCN amplifications were present, SCAs were not detectable. A 1p-loss is often 
associated with MNA in homogenously amplified NB, but MNA without any other segmental 
aberration has only been reported in very few cases in the literature. Albeit our results showed 
no commonality in large SCAs, segmental microaberrations or other mutations could still 
underlie MNA. Though, their investigation was not included in this project. Next-generation 
sequencing of the tumor DNA or of expressed genes could offer more detailed information 
whether minor alterations or expression differences play a role.  
Nonetheless, our results indeed demonstrated the association of an immense variety of 
segmental aberrations with hetMNA, including losses of 1p, 11q, 12q, and 17p and segmental 
gains of 2p, 3p, and 6p in different tumor pieces of only three patients. The most interesting 
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combination of aberrations was revealed in the four pieces of the tumor of patient #4. While 
all four pieces showed 1p-losses in one of three chromosomes in cell populations of varying 
sizes, two distinct 1p breakpoints were detectable in two tumor pieces each. Further 
investigations of the breakpoints were not undertaken and their emergence is thus subject to 
speculations. The two breaks could have developed independently from one another. The 
occurrence of the first break of the smaller aberration at a rather instable site, which 
subsequently lead to second, more stable break and a larger segmental loss, would be a 
different explanation. The 1p-losses were detected in combination with either MNA, 3q gain, 
11q-loss or no other SCA in the four respective tumor samples, which indicates the existence 
of at least four different tumor cell clones in the entire tumor. The presence of MNA and 11q-
LOH in the same tumor is remarkable since a striking inverse relationship of the two 
alterations has been confirmed in various studies [12, 126, 127]. In this case, it can also be 
assumed that MNA and 11q-LOH tumor cells constitute different populations within this 
tumor. The tumor piece displaying MNA showed no sign of 11q-loss and vice versa. 
Confirmation by a clarifying I-FISH for the presence of any combined alterations within the 
single tumor pieces has not yet been obtained. Therefore, it cannot be said whether the 
aberrations occurred in the same or in distinctive cell population in the four tumor pieces. 
Assuming that even more tumor cell clones are comprised in the entire tumor is reasonable. 
Dissection of the different tumor cell types and comparison of their genomic profile would 
allow a prediction on clonality and could potentially reveal a chronology of aberration 
emergence in the different cell populations. 
The case of patient #5 is a good example for the importance of a good tumor workup 
supporting the obligatory application of I-FISH in NB diagnostics. While the sample of the 
initial tumor showed no MNA with SNP array analysis, MYCN I-FISH identified a few tumor 
cells with amplification in touch preparations. The tumor piece removed during therapy 
showed a very prominent amplification of MYCN on the SNP array. Apparently, the primary 
tumor was resected incompletely. The remainder with a majority of MNA cells was either 
unresected or the sparse MYCN amplified cells gained a natural proliferative advantage over 
the other tumor cells or were selected for by the applied therapy. A new origination of the 
neuroblastoma is unlikely since both tumors showed almost identical numerical aberrations 
(data not shown).  
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The disclosed heterogeneity of the investigated hetMNA tumors argues for the resection 
and investigation of more, separated tumor pieces for a better identification of individual 
tumor cell clones. The effect on risk stratification and survival of coexisting NB clones and 
their potential cooperation has been largely unexplored to our knowledge and demands a more 
detailed investigation.  
 
 
4.4 Genetic instability in neuroblastoma 
 
MYCN amplification is considered to emerge rather late in the tumorigenesis of 
neuroblastoma and is thus not present in every tumor [123]. MNA is not required for NB 
development, but associates with aggressive behavior in advanced diseases and worse 
prognosis [114]. An underlying chronological order of genetic events leading to NB formation 
and in particular to MNA is yet to be identified. Earlier, we have reported that a common 
segmental aberration does not correlate with MYCN amplification in hetMNA tumors. A 
common ground, however, exists during the formation of MNA in all tumors. Genomic 
instability-entailed DNA double stand-breaks lie at the heart of the formation of both 
extrachromosomal double minutes and chromosomal homogeneously staining regions, the 
two cytogenetic manifestations of MNA in neuroblastoma [29]. Chromosomal breakage is 
necessary to initiate both the breakage-fusion-bridge cycle and the episome model. Both 
processes are considered to result in both cytogenetic manifestations of the MYCN amplicon 
[32, 37, 128]. Hence, we investigated genomic instability and DSB occurrence as a potential 
trigger for MYCN amplification and correlated γH2AX immunostaining to subsequent MYCN 
I-FISH.  
Our experiments permit the conclusion that unrepaired DNA double strand breaks, as 
visualized by γH2AX immunostaining, are detectable in tumor cells independently from 
MYCN amplification in neuroblastoma. Furthermore, MYCN amplification is present without 
a correlating γH2AX staining in tumor cells of heterogeneous and homogeneous MNA 
tumors. The overall staining was heterogeneous in pattern and mostly defuse with only a few 
foci in the nuclei of all tested tumor samples including the homogeneous references. The 
strongest staining was detected in neuroblastomas featuring a combination of MNA and 
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segmental aberrations. The difference between tumors with NCA-only and those with 
segmental aberrations is less prominent and needs to be further distinguished with more tumor 
samples. Genetically different hetMNA neuroblastoma were also different in their γH2AX 
staining pattern and can thus far not be assigned to any of the three categories of 
homogeneous neuroblastoma. Interestingly, the hetMNA tumor without SCAs showed a 
stronger staining pattern than the one with SCAs.  
The presence of MNA cells which showed dmin-typical MYCN FISH spots without 
γH2AX staining in the amplified tumor subgroups suggests that episomal MYCN 
amplification leaves no unrepaired DSBs behind when DNA damage repair is not 
compromised otherwise. Incomplete repair of the damage in γH2AX positive cells could 
potentially elicit a response towards senescence or even apoptosis, which is a typical signature 
of aggressively proliferating MNA tumor cells [129]. Interpreting MNA and γH2AX 
correlation events in terms of the state of the affected cell is therefore more complicated. 
Dual-positivity could generally indicate a high basic level of DSB presence. Alternatively, the 
already established MYCN amplification could lead to oncogene-induced DSB formation. For 
an accurate interpretation, we also need to take into account that other cellular processes lead 
to phosphorylation of γH2AX as well. Apoptotic cells also stain strongly for γH2AX and 
usually show a unique DAPI staining in the advanced apoptotic nuclei (data not shown). Early 
stages are more difficult to identify by DAPI alone but an affected cell undergoing the initial 
steps of DNA fragmentation with irreparable DSBs would still stain positive. Additionally, 
MYCN overexpression was shown to induce apoptosis in cell lines [130]. An apoptosis assay 
might help to discriminate these cells from viable γH2AX-positive tumor cells. 
Phosphorylation of H2AX has furthermore been reported in association with eroded telomeres 
[131, 132] and to occur independently from DSBs and DNA damage signaling in a cell-cycle 
dependent manner [133]. Both causations need to be excluded by further experiments in order 
to implicate genomic instability in MYCN amplification.  
A neuroblastoma without MNA presenting a MLPA-detected 11q-loss was also included in 
our investigation. The deleted region included the 11q23.2-q23.3 segment which is known to 
contain the H2AFX gene. Carén et al. recently published their results linking deletion of this 
specific region to a reduced H2AFX expression and chromosomal instability in high-risk NB 
[12]. Our results show γH2AX-positivity in a few tumor cells. Apparently, residual H2AFX 
expression still leads to DSB detection by γH2AX and supposedly to DNA damage response. 
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Correlation with 11q-deletion was, however, not examined specifically by I-FISH in the 
γH2AX-positive tumor cells.  
Although our study needs to be enlarged including more heterogeneous and homogenous 
NB tumors to support our findings, we can already conclude that MYCN amplification in 
homogeneous neuroblastoma coincides with the strongest γH2AX detection of all genetic 
subgroups. However, we cannot tie genomic instability indisputably to the accruement of 
MYCN amplification in hetMNA tumors with γH2AX immunohistochemical staining alone. 
Conducting the aforementioned experiments could aid in obtaining a clearer picture. 
Furthermore, working with cryosections of patient material gives a valuable, in vivo overview 
of the DSB presence in tumors of the different NB subcategories. However, cryosections may 
not be best suited to resolve the question whether genomic instability or the MYCN oncogene 
is responsible for the induction of DNA double strand breaks in amplified tumor cells. 
Nonetheless, combining γH2AX detection with other genetic or cellular markers has the 
potential to shed light on the surrounding circumstances of DSB induction. Additionally, 
oncogene- versus genomic instability- induced DSB formation could be investigated by 
comparing the γH2AX profile of MYCN-overexpressing to MYCN- amplified NB cell lines. 
Another interesting experiment would involve investigating the potential of MYCN-amplified 
cells to elicit a bystander response on non-amplified tumor cells. A medium transfer 
experiment of irradiated human skin fibroblasts resulted in the relay of the DSB formation 
and response to non-irradiated cells cultured independently with the medium of the irradiated 
cells [134]. The secreted soluble factors which initiated DSB formation in non-irradiated cells 
were assumed to contain signaling molecules related to ROS, such as nitric oxide. Whether 
MYCN-amplified NB cells have a similar influence on surrounding non-amplified tumor cells 
has never been examined and could help to explain the induction of DSBs in these cells, 
which were frequently found to be strongly γH2AX positive in close proximity to MNA cells 
in hetMNA tumors. 
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5 List of Abbreviations 
BFB break-fusion-bridge 
bHLH basic helix-loop-helix  
CCRI Children's Cancer Research Institute 
CIN chromosomal instability  
Cy3 cyanine 3 
D.T. during therapy 
DAPI 4',6-diamidino-2-phenylindole 
DIG digoxigenin 
dmin double-minutes 
dNTP deoxyribonucleotide 
DSB double-strand break 
FITC Fluorescein isothiocyanate 
FOV field of vision 
hetMNA heterogeneous MYCN amplification 
hsr homologous staining regions  
HU hydroxyurea 
I-FISH Interphase fluorescent in situ hybridization 
INRG International Neuroblastoma Risk Grouping 
LOH loss of heterozygosity 
MIN microsatellite instability  
MLPA Multiplex ligation-dependent probe amplification  
MNA MYCN amplification 
NCA numeric chromosomal aberration 
PCR Polymerase chain reaction 
PIN point mutation instability 
PNET peripheral neuroectodermal tumors 
SCA segmental chromosomal aberration 
SCLC small cell lung cancer 
SNP single nucleotide polymorphism 
T-ALL  T- cell acute lymphoblastic leukemia  
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6 List of Figures 
 
Figure 1: Coamplification in the MYCN amplicon is distance-related [44]. (A) 
Coamplification frequencies of the seven investigated genes on chromosome 2p24-25 in 98 
primary NB tumors. (B) Physical distance of the seven investigated genes in relation to 
MYCN, based on current BLAT assignment information [42] ............................................ 12 
Figure 2: Histopathological and interphase FISH stainings of tumor sections. All sections 
were cut at 5μm in a cryostat. (A) Histopathological HE staining of fibrous stroma-poor 
area of a NB section. (B) HE staining of a stroma-rich area of a tumor section. (C) FITC-, 
Cy3- and merged image with DAPI background of an area in a heterogeneous NB section. 
MYCN is green, D2Z red and DNA blue. White arrows mark disomic cells, red arrows 
mark tumor cell trisomic for chromosome 2 and the red arrow head a MYCN amplified cell. 
White bars, 10µm. ............................................................................................................... 32 
Figure 3: Comparison of MLPA and FISH results on MYCN amplicon detection and 
composition. Examination of a tumor DNA from patient #4 is done by MLPA (A) and SNP 
array analysis (B). The red rectangle in the MLPA readout of chromosome 2 marks the two 
MYCN probes. In the SNP array data, MYCN amplification is marked by the red arrow in 
the single-chromosome view of chromosome 2. The blue line illustrates the average copy 
number of both alleles; red (large) and green (small) lines depict allele based analyses. 
Chromosomes are represented by their cytoband information. Interphase fluorescent in situ 
hybridization (FISH) validates of MNA with MYCN (green) and D2Z (red) probes (C). 
Composition of the MYCN amplicon is confirmed with probes for MYCN (green) and 
DDX1 (red) (D). White arrows point out good examples of MYCN-amplified cells. White 
bar, 10µm. ............................................................................................................................ 35 
Figure 4: MLPA and SNP array of a heterogeneous tumor do not always correlate with MYCN 
I-FISH results. Examination of a patient’s tumor DNA is done by MLPA (A) and SNP 
array analysis (B). The black rectangle in the MLPA readout of chromosome 2 frames the 
probes often comprised in a MYCN amplicon. The SNP array data is displayed in the 
single-chromosome view of chromosome 2. The blue line illustrates the average copy 
number of both alleles; red (large) and green (small) lines depict allele based analyses. 
Chromosomes are represented by their cytoband information. Interphase fluorescent in situ 
hybridization (FISH) validates of MNA with MYCN (green) and D2Z (red) probes (C). 
Composition of the MYCN amplicon is examined with probes for MYCN (green) and NAG 
(red) (D). White arrows point out good examples of MYCN-amplified cells. White bar, 
10µm. ................................................................................................................................... 36 
Figure 5: Heterogeneity in size and composition of the MYCN amplicon in a hetMNA 
neuroblastoma. (A) MLPA data of chromosome 2 shown with a red rectangle marking the 
amplified genes. In the single-chromosome view of SNP array data on chromosome 2 is 
displayed (B). The large amplicon in marked by the black bar and the MYCN-only 
amplification by the red arrow. The blue line illustrates the average copy number of both 
alleles; red (large) and green (small) lines depict allele based analyses. Chromosomes are 
represented by their cytoband information. (C) I-FISH stainings with probes for MYCN 
(green) and DDX1 (red) were applied to illustrate the heterogeneous amplicon structure. 
DDX1-coamplified tumor cells are marked by white arrows in the upper panel. A cell 
carrying the “MYCN-only” amplicon is pictured in the lower panel. White bars, 10µm. ... 38 
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Figure 6: All genome view of SNP array data provided an excellent overview of genomic 
aberrations in tumor samples. SNP array data from patient #1 is shown in the all-genome-
view generated. The blue line illustrates the average copy number of both alleles; red 
(large) and green (small) lines depict allele based analyses. Chromosomes are represented 
by cytobands information. The red arrow points at the MYCN-location on chromosome 2, 
while black arrows mark chromosomal break points and asterisks other amplifications. For 
better visualization of segmental aberrations, gains are highlighted in transparent red and 
losses in transparent green. .................................................................................................. 40 
Figure 7: One out of four tumor pieces from patient #2 showed a 17p- deletion. SNP array 
analysis was done on the four tumor pieces of patient #2 labeled A to D. Chromosome 17 
is shown in the single-chromosome-view. The blue line illustrates the average copy 
number of both alleles; red (large) and green (small) lines depict allele based analyses. The 
chromosome is represented by the cytoband information. For better visualization of the 
17p segmental aberrations, the loss is highlighted in transparent green and the black arrow 
marks the break point. ......................................................................................................... 42 
Figure 8: MNA heterogeneity was detected in the two tumor pieces of patient #3. Pieces A 
and B were screened for chromosomal aberrations with SNP arrays. The single 
chromosome views are shown in the black boxes for chromosome 2. The MYCN amplicon 
is marked by a black bar and the location of MYCN gene indicated by the red arrow. The 
blue line illustrates the average copy number of both alleles; red (large) and green (small) 
lines depict allele based analyses. The chromosome is represented by its cytoband 
information. ......................................................................................................................... 43 
Figure 9: Four tumor pieces of patient #4 revealed extensive genetic heterogeneity. SNP array 
data of patient #4 is shown in an overview of selected single-chromosome-views generated 
with the CNAG 3.0 software. Chromosomes 1, 2, 3 and 11 were selected because of 
heterogeneous genetic aberrations. The blue line illustrates the average copy number of 
both alleles; red (large) and green (small) lines depict allele based analyses. Chromosomes 
are represented by their cytoband information. The red arrow points out the genomic 
MYCN location, while black arrows mark chromosomal break points. For better 
visualization of segmental aberrations, gains are highlighted in transparent red and losses 
in transparent green. ............................................................................................................ 45 
Figure 10: Heterogeneity of MNA was detectable in the initial tumor and in the resected 
tumor during treatment. The two pieces of patient #5 were screened for chromosomal 
aberrations with SNP arrays. Single-chromosome-views are shown for chromosome 2, 17, 
and 20. The MYCN amplicon is indicated by a red arrow. The amplification on 
chromosome 17 is marked with a blue arrow and the deletion on chromosome 20 with a 
green arrow. The blue line illustrates the average copy number of both alleles; red (large) 
and green (small) lines depict allele based analyses. The chromosome is represented by its 
cytoband............................................................................................................................... 46 
Figure 11: Heterogeneous tumors show no common segmental aberration. Affymetrix 
GeneChip® Human Mapping 250K Nsp Arrays were used to investigate the genetic 
background of hetMNA NB. The different tumor samples were compared to one another. 
The light pink color marks entire overrepresented chromosomes, light red depicts gained 
segmental aberrations and dark green lost segmental aberrations. The dark red bands 
illustrate amplifications and green bands deletions. The bands for the MYCN amplicon and 
other single-gene aberrations are slightly broadened for better visualization and do not 
resemble the actual size of the amplicon. Since the analysis of the array data is based on a 
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diploid karyotype, white color indicates disomic chromosomes. * The tumor of patient #1 
showed strong heterogeneity in the MYCN I-FISH results. ** The two compared tumor 
pieces of patient #5 were primary and during-therapy. Pat. # patient number; Tu. # tumor 
number: In initial: D.T. during therapy ............................................................................... 47 
Figure 12: MYCN amplification only partially correlates with the occurrence of DNA double 
strand breaks in hetMNA neuroblastoma. Images show combined stainings of FITC-
labeled MYCN I-FISH (left column) on Cy3-labeled γH2AX prestained cryosections 
(middle column) of hetMNA tumor pieces. Merged images of FITC, Cy3 and DAPI are 
depicted in the right column. Stainings of two tumor pieces of the same hetMNA 
neuroblastoma with NCA are displayed; one piece with a very low percentage or no MNA 
cells (A), the other with a high percentage of MNA cells (B). Two pieces of a hetMNA 
tumor with SCA are depicted in the lower two rows, one with no detectable MNA cells (C) 
the other with large areas of amplified cells (D). White arrows point at tumor cells with 
little or no γH2AX staining, red arrows at tumor cells with γH2AX staining, the arrow 
heads at double-positives, and the green arrow at a disomic cell of unknown cell type. 
White bar, 10µm. ................................................................................................................. 49 
Figure 13: γH2AX staining pattern is heterogeneous in different hetMNA neuroblastoma and 
compares weakly to homogeneous tumors. Overview images and the detailed images in the 
panel below are always from the same tumor. Overviews are stained for γH2AX and 
counterstained with DAPI. In the panel of the detailed images, MYCN- FISH is green (left 
image), γH2AX immunostaining is red (middle image). Merged images (right image) are 
counterstained with DAPI (blue). Correlated stainings are displayed for γH2AX and MYCN 
amplification in a hetMNA tumor with NCA (A) and a hetMNA tumor carrying SCAs (B). 
References of MYCN I-FISH and γH2AX immunostaining on sections of homogeneous 
NBs with NCA without MNA (C), SCAs without MNA (D) and SCAs with classic MNA 
(E) are given below. Red arrows denote positive and white arrows negative tumor cells for 
γH2AX staining. Red arrow heads identify double-positive cells. The green arrow marks a 
γH2AX positive cell of unknown cell type. White bars, 10µm. .......................................... 51 
Figure 14: “Classic” MNA neuroblastoma display areas without and with strong γH2AX 
immunostaining. Images show combined stainings of FITC-labeled MYCN I-FISH (left 
column) on Cy3-labeled γH2AX prestained cryosections (middle column) of MNA tumor 
pieces. Merged images of FITC, Cy3 and DAPI are depicted in the right column. Red 
arrows mark tumor cells with strong γH2AX positivity. Images were taken at 40-fold 
magnification with fixed integration times. White bar, 10µm. ........................................... 52 
Figure 15: Neuroblastoma with 11q-loss shows substantial γH2AX staining. MLPA displays 
prominent 11q deletion including the H2AFX gene locus (A). The detailed images (B) in 
the panel below and part of section overview (C) are from the same tumor. MYCN- FISH is 
green, γH2AX immunostaining is red and DNA is blue for all images. Images were taken 
at 40-fold magnification with fixed integration times and stitched together for the 
overview. Black rectangle marks the lost segment on chromosome 11. White arrows mark 
examples of γH2AX negative tumor cells and green arrows positive cell of unknown cell 
type. White bar, 10µm. ........................................................................................................ 53 
 
 
66 
 
7 List of Tables 
 
Table 1: Clinical and therapy data of the five patients selected for genetic analysis. .............. 20 
Table 2: MLPA reaction mixes. Depending on the number of DNA samples the reaction 
mixes were done as master mixes. All reagents were obtained from MRC Holland except 
for aqua dest. and HiDi-formamide (Applied Biosystems, Darmstadt, Germany; Cat. No. 
P/N4311320C). .................................................................................................................... 27 
 
67 
 
8 Reference  
 
1. Norman J Lacayo, M. and M. Neyssa Marina. Neuroblastoma.  2007 14.11.2007 [cited 
2009 25.02.]; Available from: http://emedicine.medscape.com/article/988284-
overview. 
2. Brodeur, G.M., et al., Revisions of the international criteria for neuroblastoma 
diagnosis, staging and response to treatment. Prog Clin Biol Res, 1994. 385: p. 363-9. 
3. Ambros, P.F., et al., Regression and progression in neuroblastoma. Does genetics 
predict tumour behaviour? Eur J Cancer, 1995. 31A(4): p. 510-5. 
4. Ambros, I.M., et al., Role of ploidy, chromosome 1p, and Schwann cells in the 
maturation of neuroblastoma. N Engl J Med, 1996. 334(23): p. 1505-11. 
5. Gisselsson, D., et al., Distinct evolutionary mechanisms for genomic imbalances in 
high-risk and low-risk neuroblastomas. J Carcinog, 2007. 6: p. 15. 
6. Spitz, R., et al., Oligonucleotide array-based comparative genomic hybridization 
(aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with 
relapse pattern and outcome. Genes Chromosomes Cancer, 2006. 45(12): p. 1130-42. 
7. Kaneko, Y., et al., Different karyotypic patterns in early and advanced stage 
neuroblastomas. Cancer Res, 1987. 47(1): p. 311-8. 
8. Spitz, R., et al., Favorable outcome of triploid neuroblastomas: a contribution to the 
special oncogenesis of neuroblastoma. Cancer Genet Cytogenet, 2006. 167(1): p. 51-
6. 
9. Seeger, R.C., et al., Association of multiple copies of the N-myc oncogene with rapid 
progression of neuroblastomas. N Engl J Med, 1985. 313(18): p. 1111-6. 
10. Attiyeh, E.F., et al., Chromosome 1p and 11q deletions and outcome in 
neuroblastoma. N Engl J Med, 2005. 353(21): p. 2243-53. 
11. Bown, N., et al., Gain of chromosome arm 17q and adverse outcome in patients with 
neuroblastoma. N Engl J Med, 1999. 340(25): p. 1954-61. 
12. Caren, H., et al., High-risk neuroblastoma tumors with 11q-deletion display a poor 
prognostic, chromosome instability phenotype with later onset. Proc Natl Acad Sci U 
S A. 107(9): p. 4323-8. 
13. Vandesompele, J., et al., Genetic heterogeneity of neuroblastoma studied by 
comparative genomic hybridization. Genes Chromosomes Cancer, 1998. 23(2): p. 
141-52. 
14. Schleiermacher, G., et al., Accumulation of segmental alterations determines 
progression in neuroblastoma. Journal of Clinical Oncology, 2010. 
15. American Cancer Society, I. Detailed Guide: Neuroblastoma What Are the Risk 
Factors for Neuroblastoma?  22.10.2008 [cited 2009 26.02]. 
16. Corvi, R., et al., MYCN is retained in single copy at chromosome 2 band p23-24 
during amplification in human neuroblastoma cells. Proc Natl Acad Sci U S A, 1994. 
91(12): p. 5523-7. 
17. Schwab, M., et al., Amplified DNA with limited homology to myc cellular oncogene is 
shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature, 
1983. 305(5931): p. 245-8. 
18. Kohl, N.E., et al., Transposition and amplification of oncogene-related sequences in 
human neuroblastomas. Cell, 1983. 35(2 Pt 1): p. 359-67. 
19. Squire, J., et al., Tumour induction by the retinoblastoma mutation is independent of 
N-myc expression. Nature, 1986. 322(6079): p. 555-7. 
68 
 
20. Zimmerman, K.A., et al., Differential expression of myc family genes during murine 
development. Nature, 1986. 319(6056): p. 780-3. 
21. Schwab, M., R. Corvi, and L.C. Amler, N-MYC oncogene amplification: a 
consequence of genomic instability in human neuroblastoma. The Neuroscientist 
1995. 1: p. 277-285. 
22. Nau, M.M., et al., Human small-cell lung cancers show amplification and expression 
of the N-myc gene. Proc Natl Acad Sci U S A, 1986. 83(4): p. 1092-6. 
23. Lee, W.H., A.L. Murphree, and W.F. Benedict, Expression and amplification of the N-
myc gene in primary retinoblastoma. Nature, 1984. 309(5967): p. 458-60. 
24. Collins, V.P., Amplified genes in human gliomas. Semin Cancer Biol, 1993. 4(1): p. 
27-32. 
25. Rouah, E., et al., N-myc amplification and neuronal differentiation in human primitive 
neuroectodermal tumors of the central nervous system. Cancer Res, 1989. 49(7): p. 
1797-801. 
26. Stanton, L.W., M. Schwab, and J.M. Bishop, Nucleotide sequence of the human N-myc 
gene. Proc Natl Acad Sci U S A, 1986. 83(6): p. 1772-6. 
27. Ibson, J.M. and P.H. Rabbitts, Sequence of a germ-line N-myc gene and amplification 
as a mechanism of activation. Oncogene, 1988. 2(4): p. 399-402. 
28. Smith, K.A., et al., Distinctive chromosomal structures are formed very early in the 
amplification of CAD genes in Syrian hamster cells. Cell, 1990. 63(6): p. 1219-27. 
29. Debatisse, M., et al., Gene amplification mechanisms: the role of fragile sites. Recent 
Results Cancer Res, 1998. 154: p. 216-26. 
30. Coquelle, A., et al., Expression of fragile sites triggers intrachromosomal mammalian 
gene amplification and sets boundaries to early amplicons. Cell, 1997. 89(2): p. 215-
25. 
31. Shimizu, N., et al., When, where and how the bridge breaks: anaphase bridge 
breakage plays a crucial role in gene amplification and HSR generation. Exp Cell 
Res, 2005. 302(2): p. 233-43. 
32. Vukovic, B., et al., Correlating breakage-fusion-bridge events with the overall 
chromosomal instability and in vitro karyotype evolution in prostate cancer. 
Cytogenet Genome Res, 2007. 116(1-2): p. 1-11. 
33. Selvarajah, S., et al., The breakage-fusion-bridge (BFB) cycle as a mechanism for 
generating genetic heterogeneity in osteosarcoma. Chromosoma, 2006. 115(6): p. 
459-67. 
34. Reshmi, S.C., et al., Inverted duplication pattern in anaphase bridges confirms the 
breakage-fusion-bridge (BFB) cycle model for 11q13 amplification. Cytogenet 
Genome Res, 2007. 116(1-2): p. 46-52. 
35. Carroll, S.M., et al., Double minute chromosomes can be produced from precursors 
derived from a chromosomal deletion. Mol Cell Biol, 1988. 8(4): p. 1525-33. 
36. Wahl, G.M., The importance of circular DNA in mammalian gene amplification. 
Cancer Res, 1989. 49(6): p. 1333-40. 
37. Von Hoff, D.D., New mechanisms of gene amplification in drug resistance (the 
episome model). Cancer Treat Res, 1991. 57: p. 1-11. 
38. Storlazzi, C.T., et al., MYC-containing double minutes in hematologic malignancies: 
evidence in favor of the episome model and exclusion of MYC as the target gene. Hum 
Mol Genet, 2006. 15(6): p. 933-42. 
69 
 
39. Yoshimoto, M., et al., MYCN gene amplification. Identification of cell populations 
containing double minutes and homogeneously staining regions in neuroblastoma 
tumors. Am J Pathol, 1999. 155(5): p. 1439-43. 
40. Storlazzi, C.T., et al., Origin and structure of MYCN-containing double minutes 
(dmin) and homogeneously staining regions (hsr) in solid tumors. Genome Research, 
2010. 
41. Hahn, P.J., Molecular biology of double-minute chromosomes. Bioessays, 1993. 15(7): 
p. 477-84. 
42. Reiter, J.L. and G.M. Brodeur, High-resolution mapping of a 130-kb core region of 
the MYCN amplicon in neuroblastomas. Genomics, 1996. 32(1): p. 97-103. 
43. Hiemstra, J.L., S.S. Schneider, and G.M. Brodeur, High-resolution mapping of the N-
myc amplicon core domain in neuroblastomas. Prog Clin Biol Res, 1994. 385: p. 51-7. 
44. Weber, A., et al., Coamplification of DDX1 correlates with an improved survival 
probability in children with MYCN-amplified human neuroblastoma. J Clin Oncol, 
2004. 22(13): p. 2681-90. 
45. George, R.E., et al., Analysis of candidate gene co-amplification with MYCN in 
neuroblastoma. Eur J Cancer, 1997. 33(12): p. 2037-42. 
46. Chen, B., S.C. Jhanwar, and M. Ladanyi, Rearrangement in the coding region of the 
MYCN gene in a subset of amplicons in a case of neuroblastoma with MYCN 
amplification. Diagn Mol Pathol, 2001. 10(2): p. 100-4. 
47. Lutz, W. and M. Schwab, In vivo regulation of single copy and amplified N-myc in 
human neuroblastoma cells. Oncogene, 1997. 15(3): p. 303-15. 
48. Theissen, J., et al., Heterogeneity of the MYCN oncogene in neuroblastoma. Clin 
Cancer Res, 2009. 15(6): p. 2085-90. 
49. Kushima, M., et al., Heterogeneity and progression of renal cell carcinomas as 
revealed by DNA cytofluorometry and the significance of the presence of polyploid 
cells. Urol Res, 1995. 23(6): p. 381-6. 
50. Sayagues, J.M., et al., Incidence of numerical chromosome aberrations in meningioma 
tumors as revealed by fluorescence in situ hybridization using 10 chromosome-
specific probes. Cytometry, 2002. 50(3): p. 153-9. 
51. Okada, S., et al., Intratumoral DNA heterogeneity of small hepatocellular carcinoma. 
Cancer, 1995. 75(2): p. 444-50. 
52. Lonn, U., et al., Intratumoral heterogeneity for amplified genes in human breast 
carcinoma. Int J Cancer, 1994. 58(1): p. 40-5. 
53. Kerbl, R., et al., Neuroblastoma with focal MYCN amplification and bone marrow 
infiltration: a staging and treatment dilemma. Med Pediatr Oncol, 2002. 38(2): p. 109-
11. 
54. Lorenzana, A.N., et al., Heterogeneity of MYCN amplification in a child with stroma-
rich neuroblastoma (ganglioneuroblastoma). Pediatr Pathol Lab Med, 1997. 17(6): p. 
875-83. 
55. Noguera, R., et al., MYCN gain and MYCN amplification in a stage 4S neuroblastoma. 
Cancer Genet Cytogenet, 2003. 140(2): p. 157-61. 
56. Negrini, S., V.G. Gorgoulis, and T.D. Halazonetis, Genomic instability--an evolving 
hallmark of cancer. Nat Rev Mol Cell Biol. 11(3): p. 220-8. 
57. Fishel, R., et al., The human mutator gene homolog MSH2 and its association with 
hereditary nonpolyposis colon cancer. Cell, 1993. 75(5): p. 1027-38. 
58. Leach, F.S., et al., Mutations of a mutS homolog in hereditary nonpolyposis colorectal 
cancer. Cell, 1993. 75(6): p. 1215-25. 
70 
 
59. Al-Tassan, N., et al., Inherited variants of MYH associated with somatic G:C-->T:A 
mutations in colorectal tumors. Nat Genet, 2002. 30(2): p. 227-32. 
60. Bielas, J.H., et al., Human cancers express a mutator phenotype. Proc Natl Acad Sci U 
S A, 2006. 103(48): p. 18238-42. 
61. Loeb, L.A., K.R. Loeb, and J.P. Anderson, Multiple mutations and cancer. Proc Natl 
Acad Sci U S A, 2003. 100(3): p. 776-81. 
62. Eshleman, J.R., et al., Increased mutation rate at the hprt locus accompanies 
microsatellite instability in colon cancer. Oncogene, 1995. 10(1): p. 33-7. 
63. Malkhosyan, S., et al., Frameshift mutator mutations. Nature, 1996. 382(6591): p. 
499-500. 
64. Terrados, G., et al., Characterization of a natural mutator variant of human DNA 
polymerase lambda which promotes chromosomal instability by compromising NHEJ. 
PLoS One, 2009. 4(10): p. e7290. 
65. Kinzler, K.W. and B. Vogelstein, Cancer-susceptibility genes. Gatekeepers and 
caretakers. Nature, 1997. 386(6627): p. 761, 763. 
66. Shen, C.Y., et al., Genome-wide search for loss of heterozygosity using laser capture 
microdissected tissue of breast carcinoma: an implication for mutator phenotype and 
breast cancer pathogenesis. Cancer Res, 2000. 60(14): p. 3884-92. 
67. Cahill, D.P., et al., Mutations of mitotic checkpoint genes in human cancers. Nature, 
1998. 392(6673): p. 300-3. 
68. Cahill, D.P., et al., Characterization of MAD2B and other mitotic spindle checkpoint 
genes. Genomics, 1999. 58(2): p. 181-7. 
69. Wang, Z., et al., Three classes of genes mutated in colorectal cancers with 
chromosomal instability. Cancer Res, 2004. 64(9): p. 2998-3001. 
70. Halazonetis, T.D., V.G. Gorgoulis, and J. Bartek, An oncogene-induced DNA damage 
model for cancer development. Science, 2008. 319(5868): p. 1352-5. 
71. Casper, A.M., et al., ATR regulates fragile site stability. Cell, 2002. 111(6): p. 779-89. 
72. Arlt, M.F., A.M. Casper, and T.W. Glover, Common fragile sites. Cytogenet Genome 
Res, 2003. 100(1-4): p. 92-100. 
73. Durkin, S.G. and T.W. Glover, Chromosome fragile sites. Annu Rev Genet, 2007. 41: 
p. 169-92. 
74. Gorgoulis, V.G., et al., Activation of the DNA damage checkpoint and genomic 
instability in human precancerous lesions. Nature, 2005. 434(7035): p. 907-13. 
75. Bartkova, J., et al., DNA damage response as a candidate anti-cancer barrier in early 
human tumorigenesis. Nature, 2005. 434(7035): p. 864-70. 
76. Di Micco, R., et al., Oncogene-induced senescence is a DNA damage response 
triggered by DNA hyper-replication. Nature, 2006. 444(7119): p. 638-42. 
77. Denko, N.C., et al., The human Ha-ras oncogene induces genomic instability in 
murine fibroblasts within one cell cycle. Proc Natl Acad Sci U S A, 1994. 91(11): p. 
5124-8. 
78. Felsher, D.W. and J.M. Bishop, Transient excess of MYC activity can elicit genomic 
instability and tumorigenesis. Proc Natl Acad Sci U S A, 1999. 96(7): p. 3940-4. 
79. Bartkova, J., et al., Oncogene-induced senescence is part of the tumorigenesis barrier 
imposed by DNA damage checkpoints. Nature, 2006. 444(7119): p. 633-7. 
80. Kastan, M.B. and J. Bartek, Cell-cycle checkpoints and cancer. Nature, 2004. 
432(7015): p. 316-23. 
81. Hollstein, M., et al., p53 mutations in human cancers. Science, 1991. 253(5015): p. 
49-53. 
71 
 
82. Stiff, T., et al., ATR-dependent phosphorylation and activation of ATM in response to 
UV treatment or replication fork stalling. EMBO J, 2006. 25(24): p. 5775-82. 
83. Stiff, T., et al., ATM and DNA-PK function redundantly to phosphorylate H2AX after 
exposure to ionizing radiation. Cancer Res, 2004. 64(7): p. 2390-6. 
84. Takahashi, A. and T. Ohnishi, Does gammaH2AX foci formation depend on the 
presence of DNA double strand breaks? Cancer Lett, 2005. 229(2): p. 171-9. 
85. Rogakou, E.P., et al., Megabase chromatin domains involved in DNA double-strand 
breaks in vivo. J Cell Biol, 1999. 146(5): p. 905-16. 
86. Stucki, M. and S.P. Jackson, gammaH2AX and MDC1: anchoring the DNA-damage-
response machinery to broken chromosomes. DNA Repair (Amst), 2006. 5(5): p. 534-
43. 
87. Rappold, I., et al., Tumor suppressor p53 binding protein 1 (53BP1) is involved in 
DNA damage-signaling pathways. J Cell Biol, 2001. 153(3): p. 613-20. 
88. van Attikum, H. and S.M. Gasser, ATP-dependent chromatin remodeling and DNA 
double-strand break repair. Cell Cycle, 2005. 4(8): p. 1011-4. 
89. Chaplet, M., et al., BRIT1/MCPH1: a guardian of genome and an enemy of tumors. 
Cell Cycle, 2006. 5(22): p. 2579-83. 
90. Chaturvedi, P., et al., Mammalian Chk2 is a downstream effector of the ATM-
dependent DNA damage checkpoint pathway. Oncogene, 1999. 18(28): p. 4047-54. 
91. Bartek, J. and J. Lukas, Chk1 and Chk2 kinases in checkpoint control and cancer. 
Cancer Cell, 2003. 3(5): p. 421-9. 
92. Alderton, G.K., et al., Regulation of mitotic entry by microcephalin and its overlap 
with ATR signalling. Nat Cell Biol, 2006. 8(7): p. 725-33. 
93. Sedelnikova, O.A., et al., Quantitative detection of (125)IdU-induced DNA double-
strand breaks with gamma-H2AX antibody. Radiat Res, 2002. 158(4): p. 486-92. 
94. Rogakou, E.P., et al., DNA double-stranded breaks induce histone H2AX 
phosphorylation on serine 139. J Biol Chem, 1998. 273(10): p. 5858-68. 
95. Bassing, C.H., et al., Histone H2AX: a dosage-dependent suppressor of oncogenic 
translocations and tumors. Cell, 2003. 114(3): p. 359-70. 
96. Thirman, M.J., et al., Rearrangement of the MLL gene in acute lymphoblastic and 
acute myeloid leukemias with 11q23 chromosomal translocations. N Engl J Med, 
1993. 329(13): p. 909-14. 
97. Parikh, R.A., et al., Loss of distal 11q is associated with DNA repair deficiency and 
reduced sensitivity to ionizing radiation in head and neck squamous cell carcinoma. 
Genes Chromosomes Cancer, 2007. 46(8): p. 761-75. 
98. Novik, K.L., et al., Genetic variation in H2AFX contributes to risk of non-Hodgkin 
lymphoma. Cancer Epidemiol Biomarkers Prev, 2007. 16(6): p. 1098-106. 
99. Srivastava, N., et al., Copy number alterations of the H2AFX gene in sporadic breast 
cancer patients. Cancer Genet Cytogenet, 2008. 180(2): p. 121-8. 
100. Celeste, A., et al., H2AX haploinsufficiency modifies genomic stability and tumor 
susceptibility. Cell, 2003. 114(3): p. 371-83. 
101. Bonner, W.M., et al., GammaH2AX and cancer. Nat Rev Cancer, 2008. 8(12): p. 957-
67. 
102. Klaunig, J.E. and L.M. Kamendulis, The role of oxidative stress in carcinogenesis. 
Annu Rev Pharmacol Toxicol, 2004. 44: p. 239-67. 
103. Hussain, S.P., L.J. Hofseth, and C.C. Harris, Radical causes of cancer. Nat Rev 
Cancer, 2003. 3(4): p. 276-85. 
72 
 
104. Tanaka, T., et al., Constitutive histone H2AX phosphorylation and ATM activation, the 
reporters of DNA damage by endogenous oxidants. Cell Cycle, 2006. 5(17): p. 1940-
5. 
105. Szekeres, T., M. Fritzer-Szekeres, and H.L. Elford, The enzyme ribonucleotide 
reductase: target for antitumor and anti-HIV therapy. Crit Rev Clin Lab Sci, 1997. 
34(6): p. 503-28. 
106. Pourquier, P. and Y. Pommier, Topoisomerase I-mediated DNA damage. Adv Cancer 
Res, 2001. 80: p. 189-216. 
107. Fortune, J.M. and N. Osheroff, Topoisomerase II as a target for anticancer drugs: 
when enzymes stop being nice. Prog Nucleic Acid Res Mol Biol, 2000. 64: p. 221-53. 
108. Takai, H., A. Smogorzewska, and T. de Lange, DNA damage foci at dysfunctional 
telomeres. Curr Biol, 2003. 13(17): p. 1549-56. 
109. d'Adda di Fagagna, F., Living on a break: cellular senescence as a DNA-damage 
response. Nat Rev Cancer, 2008. 8(7): p. 512-22. 
110. Tweddle, D.A., et al., Evidence for the development of p53 mutations after cytotoxic 
therapy in a neuroblastoma cell line. Cancer Res, 2001. 61(1): p. 8-13. 
111. Carr, J., et al., Increased frequency of aberrations in the p53/MDM2/p14(ARF) 
pathway in neuroblastoma cell lines established at relapse. Cancer Res, 2006. 66(4): 
p. 2138-45. 
112. Leslie, A., et al., Mutations of APC, K-ras, and p53 are associated with specific 
chromosomal aberrations in colorectal adenocarcinomas. Cancer Res, 2003. 63(15): 
p. 4656-61. 
113. Yaari, S., et al., Disruption of cooperation between Ras and MycN in human 
neuroblastoma cells promotes growth arrest. Clin Cancer Res, 2005. 11(12): p. 4321-
30. 
114. Maris, J.M., et al., Neuroblastoma. Lancet, 2007. 369(9579): p. 2106-20. 
115. Ambros, P.F., et al., International consensus for neuroblastoma molecular 
diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology 
Committee. Br J Cancer, 2009. 100(9): p. 1471-82. 
116. Nannya, Y., et al., A robust algorithm for copy number detection using high-density 
oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res, 2005. 
65(14): p. 6071-9. 
117. Yamamoto, G., et al., Highly sensitive method for genomewide detection of allelic 
composition in nonpaired, primary tumor specimens by use of affymetrix single-
nucleotide-polymorphism genotyping microarrays. Am J Hum Genet, 2007. 81(1): p. 
114-26. 
118. Villamon, E., et al., Comparison of different techniques for the detection of genetic 
risk-identifying chromosomal gains and losses in neuroblastoma. Virchows Arch, 
2008. 453(1): p. 47-55. 
119. Haupt, Y., et al., Mdm2 promotes the rapid degradation of p53. Nature, 1997. 
387(6630): p. 296-9. 
120. Huguet, E.L., et al., Differential expression of human Wnt genes 2, 3, 4, and 7B in 
human breast cell lines and normal and disease states of human breast tissue. Cancer 
Res, 1994. 54(10): p. 2615-21. 
121. Albertson, D.G., Gene amplification in cancer. Trends Genet, 2006. 22(8): p. 447-55. 
122. Cohn, S.L., et al., The International Neuroblastoma Risk Group (INRG) classification 
system: an INRG Task Force report. J Clin Oncol, 2009. 27(2): p. 289-97. 
73 
 
123. Brodeur, G.M., et al., Amplification of N-myc in untreated human neuroblastomas 
correlates with advanced disease stage. Science, 1984. 224(4653): p. 1121-4. 
124. Graux, C., et al., Heterogeneous patterns of amplification of the NUP214-ABL1 fusion 
gene in T-cell acute lymphoblastic leukemia. Leukemia, 2009. 23(1): p. 125-33. 
125. Weber, A., et al., The coamplification pattern of the MYCN amplicon is an invariable 
attribute of most MYCN-amplified human neuroblastomas. Clin Cancer Res, 2006. 
12(24): p. 7316-21. 
126. Guo, C., et al., Deletion of 11q23 is a frequent event in the evolution of MYCN single-
copy high-risk neuroblastomas. Med Pediatr Oncol, 2000. 35(6): p. 544-6. 
127. Spitz, R., et al., Loss in chromosome 11q identifies tumors with increased risk for 
metastatic relapses in localized and 4S neuroblastoma. Clin Cancer Res, 2006. 12(11 
Pt 1): p. 3368-73. 
128. Shimizu, N., et al., Amplification of plasmids containing a mammalian replication 
initiation region is mediated by controllable conflict between replication and 
transcription. Cancer Res, 2003. 63(17): p. 5281-90. 
129. Shimada, H., et al., The International Neuroblastoma Pathology Classification (the 
Shimada system). Cancer, 1999. 86(2): p. 364-72. 
130. Paffhausen, T., M. Schwab, and F. Westermann, Targeted MYCN expression affects 
cytotoxic potential of chemotherapeutic drugs in neuroblastoma cells. Cancer Lett, 
2007. 250(1): p. 17-24. 
131. Olive, P.L., Endogenous DNA breaks: gammaH2AX and the role of telomeres. Aging 
(Albany NY), 2009. 1(2): p. 154-6. 
132. Nakamura, A.J., et al., Telomere-dependent and telomere-independent origins of 
endogenous DNA damage in tumor cells. Aging (Albany NY), 2009. 1(2): p. 212-8. 
133. Ichijima, Y., et al., Phosphorylation of histone H2AX at M phase in human cells 
without DNA damage response. Biochem Biophys Res Commun, 2005. 336(3): p. 
807-12. 
134. Han, W., et al., The early and initiation processes of radiation-induced bystander 
effects involved in the induction of DNA double strand breaks in non-irradiated 
cultures. Br J Radiol, 2007. 80 Spec No 1: p. S7-12. 
 
 
  
74 
 
Curriculum Vitae 
 
Personal data 
Name     Dominik Bogen 
Date and place of birth:   28.01.1985, Bonn- Bad Godesberg, Germany 
Nationality:    Germany 
 
Education 
09/1995 – 07/2001   Konrad Adenauer Gymnasium, Meckenheim, Germany 
08/2001 – 07/2004   German School Washington, D.C., Potomac, M.D., USA 
09/2004 – 06/2010  Studies of Molecular Biology, University of Vienna, Vienna, Austria 
 
Research Experience 
08/2005  Internship at the Laboratory of Immunology, University Clinic Bonn, Bonn, 
Germany  
Laboratory of Jacob Nattermann, M.D. and Ulrich Spengler, M.D. 
Investigation of surface receptors on human HIV/HCV infected T-
lymphocytes 
Nattermann, J. et al. Hepatitis C virus-induced secretion of inflammatory 
chemokines preferentially recruits NKG2A+CD8+ T cells. J Infect Dis 198, 
213-7 (2008). 
 
08/2006 Internship at the Laboratory of Immunology, University Clinic, Bonn, 
Germany 
Laboratory of Jacob Nattermann, M.D. and Ulrich Spengler, M.D. 
 
07/2007 – 08/2007 Internship at the Laboratory of Mammalian Genes and Development, 
National Institute of Child Health and Human Development, National 
Institutes of Health (NIH), Bethesda, MD, USA 
 Laboratory of Heiner Westphal, M.D. 
 Examination of the role of LDB1 in a valvular defect in Mus Musculus 
 
09/2008 – 10/2008 Internship at the Laboratory of Immunology, Medical University Vienna, 
Vienna, Austria  
 Laboratory of Herbert Strobl, M.D. 
 Investigation of Langerhans cell behavior upon stimulation with different 
antigens 
 
03/2009 – 05/2010 Diploma Thesis at the CHILDREN'S CANCER RESEARCH INSTITUTE, 
St. Anna Kinderkrebsforschung, Vienna, Austria 
Laboratory of Peter Ambros, PhD 
Heterogeneous MYCN amplification neuroblastoma - amplicons, genetic 
background, and genomic instability 
75 
 
Acknowledgements 
 
First, I want to express my gratitude to Peter Ambros for giving me the opportunity to work 
on this interesting project which led to this diploma thesis, for his support along the way and 
for his confidence in me to handle the numerous conferences and meetings he sent me to. I 
also want to thank my colleagues in the lab, Inge Ambros for the fruitful discussions of my 
data, Bettina Brunner and Andrea Ziegler for the introduction to the different procedures, and 
Sabine Taschner-Mandl, Eva Bozsaky and Heidi Binder for their support and advice. I am 
also much obliged to Max Kauer for his help with the SNP array data visualization. Thank 
you to all the other wonderful people at the CCRI for the great working atmosphere.  
A note of thanks goes also to the contributors outside of the CCRI, Tommy Martinsson and 
Jennie Erichsen for the SNP arrays, Tilmann Johannes and Rudolf Drescher for their help 
with the automatic microscope, and Reginald Bittner for his insights on the γH2AX 
immunostaining. I also wish to thank Hans Rotheneder for being the supervisor of my 
diploma thesis at the University of Vienna. 
Furthermore, I want to thank all my friends for their friendship and loyalty.  
Last but not least, I owe my utmost gratitude to my parents and my siblings for their 
unswerving support, encouragement, and inspiration. 
 
